WO2014113695A1 - Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists - Google Patents
Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists Download PDFInfo
- Publication number
- WO2014113695A1 WO2014113695A1 PCT/US2014/012083 US2014012083W WO2014113695A1 WO 2014113695 A1 WO2014113695 A1 WO 2014113695A1 US 2014012083 W US2014012083 W US 2014012083W WO 2014113695 A1 WO2014113695 A1 WO 2014113695A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agonist
- vitamin
- subject
- beta
- retinoic acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 120
- 235000009200 high fat diet Nutrition 0.000 title claims abstract description 66
- 102000003702 retinoic acid receptors Human genes 0.000 title claims description 82
- 108090000064 retinoic acid receptors Proteins 0.000 title claims description 82
- 208000010011 Vitamin A Deficiency Diseases 0.000 title claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 23
- 201000010099 disease Diseases 0.000 title claims description 17
- 239000000018 receptor agonist Substances 0.000 title description 2
- 229940044601 receptor agonist Drugs 0.000 title description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 186
- 102100033909 Retinoic acid receptor beta Human genes 0.000 claims abstract description 185
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 166
- 239000000556 agonist Substances 0.000 claims abstract description 147
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 147
- 239000011719 vitamin A Substances 0.000 claims abstract description 147
- 229940045997 vitamin a Drugs 0.000 claims abstract description 147
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 146
- 210000004185 liver Anatomy 0.000 claims abstract description 84
- 210000003734 kidney Anatomy 0.000 claims abstract description 57
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 44
- 210000000056 organ Anatomy 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 208000008589 Obesity Diseases 0.000 claims abstract description 14
- 235000020824 obesity Nutrition 0.000 claims abstract description 13
- 108091008761 retinoic acid receptors β Proteins 0.000 claims description 184
- HSAOETBFVAWNRP-UHFFFAOYSA-N 4-[4-(2-butoxyethoxy)-5-methyl-1,3-thiazol-2-yl]-2-fluorobenzoic acid Chemical group S1C(C)=C(OCCOCCCC)N=C1C1=CC=C(C(O)=O)C(F)=C1 HSAOETBFVAWNRP-UHFFFAOYSA-N 0.000 claims description 83
- 230000003247 decreasing effect Effects 0.000 claims description 49
- 210000000496 pancreas Anatomy 0.000 claims description 41
- 229940122338 Vitamin agonist Drugs 0.000 claims description 39
- 230000001965 increasing effect Effects 0.000 claims description 29
- 210000002966 serum Anatomy 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 25
- 210000001550 testis Anatomy 0.000 claims description 24
- 208000019423 liver disease Diseases 0.000 claims description 23
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 22
- 230000036542 oxidative stress Effects 0.000 claims description 21
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 21
- 210000004024 hepatic stellate cell Anatomy 0.000 claims description 20
- 208000017169 kidney disease Diseases 0.000 claims description 17
- 229960004666 glucagon Drugs 0.000 claims description 15
- 102000051325 Glucagon Human genes 0.000 claims description 14
- 108060003199 Glucagon Proteins 0.000 claims description 14
- 208000016222 Pancreatic disease Diseases 0.000 claims description 14
- 208000010706 fatty liver disease Diseases 0.000 claims description 14
- 230000002757 inflammatory effect Effects 0.000 claims description 14
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 13
- 230000002440 hepatic effect Effects 0.000 claims description 13
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 12
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 102000007469 Actins Human genes 0.000 claims description 9
- 108010085238 Actins Proteins 0.000 claims description 9
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- HXBKPYIEQLLNBK-UHFFFAOYSA-N 4-(4-octylphenyl)benzoic acid Chemical group C1=CC(CCCCCCCC)=CC=C1C1=CC=C(C(O)=O)C=C1 HXBKPYIEQLLNBK-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 238000009825 accumulation Methods 0.000 claims description 7
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 7
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 5
- 206010022489 Insulin Resistance Diseases 0.000 claims description 5
- 230000004761 fibrosis Effects 0.000 claims description 5
- 208000004104 gestational diabetes Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000003914 insulin secretion Effects 0.000 claims description 5
- GREHPZMOJNYZIO-QXBAZQDESA-N retinoyl coa Chemical compound C([C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C2=NC=NC(N)=C2N=C1)OP(O)(O)=O)OP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C GREHPZMOJNYZIO-QXBAZQDESA-N 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 210000002460 smooth muscle Anatomy 0.000 claims description 3
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 claims description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 230000008798 inflammatory stress Effects 0.000 claims description 2
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 26
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 6
- 208000019622 heart disease Diseases 0.000 abstract description 4
- 208000000412 Avitaminosis Diseases 0.000 abstract description 2
- 206010020772 Hypertension Diseases 0.000 abstract description 2
- 206010021135 Hypovitaminosis Diseases 0.000 abstract description 2
- 208000006011 Stroke Diseases 0.000 abstract description 2
- 230000034994 death Effects 0.000 abstract description 2
- 231100000517 death Toxicity 0.000 abstract description 2
- 230000005802 health problem Effects 0.000 abstract description 2
- 231100000518 lethal Toxicity 0.000 abstract description 2
- 230000001665 lethal effect Effects 0.000 abstract description 2
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 2
- 201000008482 osteoarthritis Diseases 0.000 abstract description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 2
- 230000000391 smoking effect Effects 0.000 abstract description 2
- 208000030401 vitamin deficiency disease Diseases 0.000 abstract description 2
- 101001132698 Homo sapiens Retinoic acid receptor beta Proteins 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 136
- 210000004027 cell Anatomy 0.000 description 87
- 230000014509 gene expression Effects 0.000 description 84
- 235000005911 diet Nutrition 0.000 description 78
- 230000037213 diet Effects 0.000 description 78
- 230000004069 differentiation Effects 0.000 description 70
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 64
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 42
- 235000020940 control diet Nutrition 0.000 description 41
- 238000011160 research Methods 0.000 description 36
- 229930002330 retinoic acid Natural products 0.000 description 34
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 33
- 210000001519 tissue Anatomy 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 32
- 229960001727 tretinoin Drugs 0.000 description 31
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 26
- VYGQUTWHTHXGQB-FFHKNEKCSA-N retinyl palmitate Natural products CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 26
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 25
- 239000003925 fat Substances 0.000 description 25
- 239000002953 phosphate buffered saline Substances 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 24
- 150000004492 retinoid derivatives Chemical class 0.000 description 24
- 239000008103 glucose Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 230000002124 endocrine Effects 0.000 description 22
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- 210000004153 islets of langerhan Anatomy 0.000 description 22
- 102000004877 Insulin Human genes 0.000 description 21
- 108090001061 Insulin Proteins 0.000 description 21
- 229940125396 insulin Drugs 0.000 description 21
- 230000009996 pancreatic endocrine effect Effects 0.000 description 20
- 230000011664 signaling Effects 0.000 description 19
- 235000020944 retinol Nutrition 0.000 description 18
- 239000011607 retinol Substances 0.000 description 18
- 229960003471 retinol Drugs 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 230000007423 decrease Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 210000001671 embryonic stem cell Anatomy 0.000 description 14
- 210000003890 endocrine cell Anatomy 0.000 description 14
- 108010059301 retinoic acid receptor gamma Proteins 0.000 description 14
- 229940108325 retinyl palmitate Drugs 0.000 description 14
- 235000019172 retinyl palmitate Nutrition 0.000 description 14
- 239000011769 retinyl palmitate Substances 0.000 description 14
- 238000010186 staining Methods 0.000 description 14
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 150000002632 lipids Chemical class 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- 108091023040 Transcription factor Proteins 0.000 description 12
- 238000013116 obese mouse model Methods 0.000 description 12
- 102000040945 Transcription factor Human genes 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 230000003292 diminished effect Effects 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 230000006372 lipid accumulation Effects 0.000 description 10
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 10
- 239000003643 water by type Substances 0.000 description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 230000024245 cell differentiation Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 239000012188 paraffin wax Substances 0.000 description 8
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 7
- 108010075254 C-Peptide Proteins 0.000 description 7
- 108010022037 Retinoic Acid 4-Hydroxylase Proteins 0.000 description 7
- 102000012211 Retinoic Acid 4-Hydroxylase Human genes 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 210000001900 endoderm Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 6
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 6
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 6
- 101150081664 PAX6 gene Proteins 0.000 description 6
- 208000001647 Renal Insufficiency Diseases 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 201000006370 kidney failure Diseases 0.000 description 6
- 230000015031 pancreas development Effects 0.000 description 6
- 102000013415 peroxidase activity proteins Human genes 0.000 description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000000018 Chemokine CCL2 Human genes 0.000 description 5
- 241001622557 Hesperia Species 0.000 description 5
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 5
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 5
- 101150066717 Rara gene Proteins 0.000 description 5
- HUDSYNWJCPDHLL-CJLVFECKSA-N [(E)-[2-(6-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate Chemical compound CC(=O)O\N=C1\C(=Nc2ccccc12)c1c(O)[nH]c2cc(Br)ccc12 HUDSYNWJCPDHLL-CJLVFECKSA-N 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 230000004153 glucose metabolism Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 238000003125 immunofluorescent labeling Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 5
- 210000004923 pancreatic tissue Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 229960000342 retinol acetate Drugs 0.000 description 5
- 235000019173 retinyl acetate Nutrition 0.000 description 5
- 239000011770 retinyl acetate Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 208000002705 Glucose Intolerance Diseases 0.000 description 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 4
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 4
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 102100038553 Neurogenin-3 Human genes 0.000 description 4
- 101710096141 Neurogenin-3 Proteins 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 4
- 229960002916 adapalene Drugs 0.000 description 4
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000011712 cell development Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000005084 renal tissue Anatomy 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 101710186630 Insulin-1 Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 208000031074 Reinjury Diseases 0.000 description 3
- 108091027981 Response element Proteins 0.000 description 3
- 102000005157 Somatostatin Human genes 0.000 description 3
- 108010056088 Somatostatin Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000021068 Western diet Nutrition 0.000 description 3
- 108010023082 activin A Proteins 0.000 description 3
- 229960001445 alitretinoin Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002304 esc Anatomy 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- -1 or particulates Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 3
- 229960000553 somatostatin Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 229960000565 tazarotene Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FRTYVAKGTFXRNY-CSKARUKUSA-N 3-chloro-4-[(e)-2-(5,5-dimethyl-8-phenyl-6h-naphthalen-2-yl)ethenyl]benzoic acid Chemical compound C12=CC(\C=C\C=3C(=CC(=CC=3)C(O)=O)Cl)=CC=C2C(C)(C)CC=C1C1=CC=CC=C1 FRTYVAKGTFXRNY-CSKARUKUSA-N 0.000 description 2
- QCSYBKHFYYISTQ-KPKJPENVSA-N 4-[(e)-3-hydroxy-3-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(O)\C=C\C1=CC=C(C(O)=O)C=C1 QCSYBKHFYYISTQ-KPKJPENVSA-N 0.000 description 2
- SWIWERVMTLKNLQ-UHFFFAOYSA-N 6-[4-methoxy-3-(1-methylcyclohexyl)phenyl]naphthalene-2-carboxylic acid Chemical compound COC1=CC=C(C=2C=C3C=CC(=CC3=CC=2)C(O)=O)C=C1C1(C)CCCCC1 SWIWERVMTLKNLQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 101100008049 Caenorhabditis elegans cut-5 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 2
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 2
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 description 2
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 2
- 101001061911 Homo sapiens Ras-related protein Rab-40A Proteins 0.000 description 2
- 101150034518 Iapp gene Proteins 0.000 description 2
- 101150089655 Ins2 gene Proteins 0.000 description 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 102100029553 Ras-related protein Rab-40A Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102100021947 Survival motor neuron protein Human genes 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 101100072652 Xenopus laevis ins-b gene Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000019169 all-trans-retinol Nutrition 0.000 description 2
- 239000011717 all-trans-retinol Substances 0.000 description 2
- 229940100609 all-trans-retinol Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000008355 dextrose injection Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 210000004039 endoderm cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000006718 epigenetic regulation Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000009707 neogenesis Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000005305 organ development Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 208000024691 pancreas disease Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000011422 pharmacological therapy Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108010079850 retinoic acid receptor beta Proteins 0.000 description 2
- 102000027483 retinoid hormone receptors Human genes 0.000 description 2
- 108091008679 retinoid hormone receptors Proteins 0.000 description 2
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- YZZAIQOVMHVWBS-UHFFFAOYSA-N 4-(5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,4]benzodiazepin-13-yl)benzoic acid Chemical compound C12=CC=CC=C2N(C)C2=CC(C(CCC3(C)C)(C)C)=C3C=C2N=C1C1=CC=C(C(O)=O)C=C1 YZZAIQOVMHVWBS-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- VUODRPPTYLBGFM-CMDGGOBGSA-N BMS-453 Chemical compound C12=CC(\C=C\C=3C=CC(=CC=3)C(O)=O)=CC=C2C(C)(C)CC=C1C1=CC=CC=C1 VUODRPPTYLBGFM-CMDGGOBGSA-N 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 1
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 1
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 102000006754 Hepatocyte Nuclear Factor 1 Human genes 0.000 description 1
- 108010086512 Hepatocyte Nuclear Factor 1 Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000601647 Homo sapiens Paired box protein Pax-6 Proteins 0.000 description 1
- 101000665882 Homo sapiens Retinol-binding protein 4 Proteins 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-M NAD(1-) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-M 0.000 description 1
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 1
- 108050000588 Neurogenic differentiation factor 1 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100037506 Paired box protein Pax-6 Human genes 0.000 description 1
- 101710144033 Pancreas/duodenum homeobox protein 1 Proteins 0.000 description 1
- 102000052651 Pancreatic hormone Human genes 0.000 description 1
- 101800001268 Pancreatic hormone Proteins 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101150075928 Pax4 gene Proteins 0.000 description 1
- 241000030360 Peromyscus truei Species 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 1
- 101150111584 RHOA gene Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 102100038246 Retinol-binding protein 4 Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002783 anti-lipogenic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 210000001100 crypt cell Anatomy 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000007184 endocrine pathway Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002907 exocrine cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000036397 gastrointestinal physiology Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000009716 hepatic expression Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 101150032953 ins1 gene Proteins 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003910 liver physiology Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000004457 myocytus nodalis Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004287 null lymphocyte Anatomy 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000004025 pancreas hormone Substances 0.000 description 1
- 230000010003 pancreatic endocrine function Effects 0.000 description 1
- 210000003577 pancreatic endocrine progenitor Anatomy 0.000 description 1
- 229940032957 pancreatic hormone Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000008886 response to retinoic acid Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 108091008726 retinoic acid receptors α Proteins 0.000 description 1
- 102000021439 retinoid binding proteins Human genes 0.000 description 1
- 108091011071 retinoid binding proteins Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 231100000337 synergistic cytotoxicity Toxicity 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000035903 transrepression Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000003820 β-cell dysfunction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Definitions
- the invention relates to the treatment and prevention of various diseases or conditions caused by fat accumulation or vitamin deficiency.
- High fat diet After smoking, high fat diet is said to be the second most lethal habit, causing 300,000 deaths each year in the U.S. alone.
- High fat diet leads to many health problems, including obesity, stroke, cancer, high blood pressure, diabetes, osteoarthritis, rheumatoid arthritis, multiple sclerosis, heart disease, and diseases in other organs such as liver and kidney.
- Diabetes is a group of pancreatic diseases characterized by high blood glucose levels that result from defects in the body's ability to produce and/or use insulin.
- 201 1 there were an estimated 366 million cases of diabetes worldwide, according to the International Diabetes Federation, and these cases are estimated to increase to 522 million by 2030 (1, 2).
- U.S. there were 23.7 million diagnosed cases, with an estimated healthcare cost of $ 113 billion (2, 3).
- Diabetes results when insulin production by pancreatic ⁇ -cells does not meet the metabolic demand of peripheral tissues such as liver, fat, and muscle (4). A reduction in ⁇ -cell number and function leads to hyperglycemia in both type I and type II diabetes (4).
- pancreatic ⁇ -cells lose self-tolerance and this gives rise to hyperglycemia (5).
- hyperglycemia a progressive hyperglycemia (5).
- type I diabetes insulin-producing pancreatic ⁇ -cells lose self-tolerance and this gives rise to hyperglycemia (5).
- Each year in the United States there are over 30,000 new cases of type I diabetes diagnosed (6).
- Patients with type I diabetes can control their blood glucose level with insulin supplements (7).
- the differentiation of stem cells into pancreatic ⁇ -cells could be a long term, better solution (8-10).
- Type II diabetes is more common. In type II diabetes the body does not use insulin properly, thus it is called insulin resistance. At first, the pancreas may make extra insulin to make up for it. But over time there won't be enough insulin to keep blood glucose at normal levels. Type II diabetes is an increasingly prevalent disease that due to a high frequency of complications leads to a significant reduction of life expectancy. Because of diabetes associated microvascular complications, type II diabetes is currently the most frequent cause of adult-onset loss of vision, renal failure, and amputations in the industrialized world. In addition, the presence of type II diabetes is associated with a two to five fold increase in cardiovascular disease risk. After long duration of disease, most patients with type II diabetes will eventually fail on oral therapy and become insulin dependent with the necessity for daily injections and multiple daily glucose measurements.
- gestational diabetes A third type of diabetes, gestational diabetes, is developed by many women usually around the 24th week of pregnancy. Treatment for gestational diabetes aims to keep blood glucose levels equal to those of pregnant women who don't have gestational diabetes.
- diabetes Some patients with diabetes can manage their conditions with healthy eating and exercise. Some will need to have prescribed medications and/or insulin to keep blood glucose levels. In addition, diabetes is a progressive disease. Even if medication is not required at first, it may be needed overtime.
- Non-alcoholic fatty liver disease is marked by lipid accumulation in hepatocytes (steatosis) without evidence of hepatitis or liver fibrosis (69, 70).
- NAFLD non-alcohol steatohepatitis
- hepatocellular carcinoma 731
- NAFLD non-alcohol steatohepatitis
- 69 hepatocellular carcinoma
- HSCs hepatic stellate cells
- VA total body vitamin A pool
- HSCs proliferate and become highly fibrotic through hyper-secretion collal and a-SMA leading to liver scarring and an inflammation cascade that drives further hepatic fibrosis and liver damage (72,73).
- kidney failure is the most common cause of kidney failure, accounting for nearly 44 percent of new cases. Even when diabetes is controlled, the disease can lead to Chronic Kidney Disease (CKD) and kidney failure. Nearly 24 million people in the United States have diabetes, and nearly 180,000 people are living with kidney failure as a result of diabetes. People with kidney failure undergo either dialysis, an artificial blood-cleaning process, or transplantation to receive a healthy kidney from a donor. In 2005, care for patients with kidney failure cost the United States nearly $32 billion.
- CKD Chronic Kidney Disease
- This invention discloses pharmaceutical compositions and methods for treating and preventing diseases in pancreas, liver, kidney, testes, as well as other organs that are associated with high fat diet and/or vitamin A deficiency.
- the invention provides a method of treating or preventing a pancreatic disease in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ⁇ 5).
- RAR ⁇ 5 retinoic acid receptor-beta
- the pancreatic disease is associated with obesity.
- the pancreatic disease is associated with a high fat diet.
- the pancreatic disease is associated with vitamin A deficiency in the pancreas.
- the pancreatic disease may be diabetes, which may be type I or type II diabetes, or gestational diabetes.
- the invention provides a method of increasing RARP level in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
- RARP retinoic acid receptor-beta
- RAR level is increased in an organ.
- the organ may be pancreas, liver, kidney, or testes.
- the invention provides a method of treating or preventing the degeneration of pancreatic beta cells in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
- RAR retinoic acid receptor-beta
- the invention provides a method of maintaining or improving the function of pancreatic beta cells in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
- RAR retinoic acid receptor-beta
- the invention provides a method of maintaining or improving pancreatic insulin secretion in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
- RAR retinoic acid receptor-beta
- the invention provides a method of maintaining or improving insulin sensitivity in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
- RAR retinoic acid receptor-beta
- the invention provides a method of maintaining or improving the level of glucagon in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
- the invention provides a method of treating or preventing fat deposit of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
- RARP retinoic acid receptor-beta
- the invention provides a method of treating or preventing inflammation of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
- RARP retinoic acid receptor-beta
- the invention provides a method of decreasing the level of an inflammatory mediator in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
- RARP retinoic acid receptor-beta
- the invention provides a method of decreasing oxidative stress in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
- RARP retinoic acid receptor-beta
- the production of the inflammatory mediator is decreased.
- the secretion of the inflammatory mediator is decreased.
- the inflammatory mediator may be monocyte chemotactic protein (mcp-1) or tumor necrosis factor alpha (tnf-d) according to certain embodiments.
- mcp-1 monocyte chemotactic protein
- tnf-d tumor necrosis factor alpha
- the fat deposit, inflammation or oxidative stress is in an organ.
- the organ may be pancreas, liver, kidney, or testes.
- the invention provides a method of treating or preventing a liver disease in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
- RAR retinoic acid receptor-beta
- the liver disease is associated with obesity.
- the liver disease is associated with a high fat diet.
- the liver disease is associated with vitamin A deficiency.
- the liver disease is fatty liver disease (FLD), liver fibrosis, or hepatic steatosis.
- FLD fatty liver disease
- liver fibrosis or hepatic steatosis.
- the liver disease is non-alcoholic FLD (NAFLD), alcohol associated FLD, or non-alcoholic steatohepatitis (NASH).
- NAFLD non-alcoholic FLD
- NASH non-alcoholic steatohepatitis
- the liver disease is associated with reduced vitamin A level in the liver.
- the invention provides a method of decreasing the activation of hepatic stellate cells (HSCs) in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
- HSCs hepatic stellate cells
- RAR retinoic acid receptor-beta
- the invention provides a method of decreasing the level of hepatic reactive oxygen species (ROS) in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
- ROS hepatic reactive oxygen species
- the invention provides a method of decreasing the level of alpha smooth muscle actin (a-SMA) in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
- a-SMA alpha smooth muscle actin
- RARP retinoic acid receptor-beta
- the invention provides a method of increasing the level of lethicin:retinol acyltransferase (LRAT) in the liver of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
- LRAT lethicin:retinol acyltransferase
- the invention provides a method of increasing the level of RAR in the liver of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
- RARP retinoic acid receptor-beta
- the invention provides a method of decreasing the level of SRBPlc in the liver of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
- RARP retinoic acid receptor-beta
- the subject has a liver disease.
- the liver disease is fatty liver disease (FLD), liver fibrosis, or hepatic steatosis.
- FLD fatty liver disease
- liver fibrosis or hepatic steatosis.
- the liver disease is non-alcoholic FLD (NAFLD), alcohol associated FLD, or non-alcoholic steatohepatitis (NASH).
- NAFLD non-alcoholic FLD
- NASH non-alcoholic steatohepatitis
- the liver disease is associated with reduced vitamin A level in the liver.
- the liver disease is associated with a pancreas disease.
- the invention provides a method of treating or preventing a kidney disease in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
- RAR retinoic acid receptor-beta
- the kidney disease is associated with obesity.
- the kidney disease is associated with a high fat diet.
- the kidney disease is kidney fibrosis.
- the kidney disease is a chronic kidney disease.
- the kidney disease is associated with a pancreatic disease.
- the kidney disease is associated with a liver disease.
- the kidney disease is associated with reduced vitamin A level in the kidney.
- the invention provides a method of increasing the level of lethicin:retinol acyltransferase (LRAT) in the kidney of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
- LRAT lethicin:retinol acyltransferase
- the invention provides a method of treating or preventing a disease associated with an organ-specific vitamin A deficiency in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARp).
- RARp retinoic acid receptor-beta
- the organ-specific vitamin A deficiency is associated with obesity.
- the organ-specific vitamin A deficiency is associated with a high fat diet.
- the subject has a normal serum level of vitamin A or retinyl esters.
- the organ may be pancreas, liver, or kidney.
- the invention provides a method of treating or preventing fibrosis in a subject comprising administering to the subject an agonist of retinoic acid receptor-beta (RAR ).
- RAR retinoic acid receptor-beta
- the invention provides a method of decreasing the accumulation of fat in a subject comprising administering to the subject an agonist of retinoic acid receptor-beta (RAR ).
- RAR retinoic acid receptor-beta
- the fibrosis or accumulation of fat is in an organ.
- the organ may pancreas, liver, kidney, or testes.
- the vitamin A or agonist of retinoic acid receptor-beta is administered at an amount from 30-200 mg per day.
- the vitamin A or agonist is administered at an amount from 50-
- the vitamin A or agonist is administered at an amount from 50- 100 mg per day/
- the vitamin A or agonist is administered at an amount from 100- 150 mg per day.
- the vitamin A or agonist of retinoic acid receptor-beta is administered orally.
- the vitamin A or agonist of retinoic acid receptor-beta is administered intravenously or subcutaneously.
- the vitamin A or agonist of retinoic acid receptor-beta (RAR ) does not elevate serum triglyceride in the subject.
- the vitamin A or agonist of retinoic acid receptor-beta does not increase cardiovascular risk in the subject.
- RAR is administered.
- both vitamin A and an agonist of RARP are both administered to the subject.
- vitamin A and an agonist of RARP are administered concomitantly.
- vitamin A and an agonist of RARP are administered sequentially.
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising vitamin A or an agonist of retinoic acid receptor-beta (RARP) or a pharmaceutically acceptable salt thereof at an amount from about 1 Omg to about 60 mg.
- RARP retinoic acid receptor-beta
- the amount of the vitamin A or agonist is from 15 mg to about 50 mg.
- the amount of the vitamin A or agonist is from 15 mg to about 35 mg.
- the amount of the vitamin A or agonist is from about 35 mg to about 50 mg.
- the amount of the vitamin A or agonist is from about 30 mg to about 200 mg.
- the amount of the vitamin A or agonist is from about 50 mg to about 150 mg.
- the amount of the vitamin A or agonist is from about 50 mg to about 100 mg.
- the amount of the vitamin A or agonist is from about 100 mg to about 150 mg.
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising vitamin A or an agonist of retinoic acid receptor-beta (RARP) or a pharmaceutically acceptable salt thereof at a concentration from about 0.1 mg to about 10 mg per 100 ml.
- RARP retinoic acid receptor-beta
- the concentration is from about 0.5 mg to about 5 mg per 100 ml.
- the concentration is from about 1 mg to about 2.5 mg per 100 ml.
- the agonist is a highly specific ⁇ agonist.
- the agonist is AC261066.
- the agonist is AC55649.
- the pharmaceutical composition comprises both vitamin A and an agonist of ⁇ .
- FIG. 1 Pancreatic endocrine differentiation protocol and its impact on the molecular level.
- A Schematic representation of the endocrine differentiation protocol adapted from D'Amour et al. (2006) used on mouse ES cells. Briefly, embryonic stem (ES) cells are treated with different growth factors to successively differentiate into definitive endoderm (DE), pancreatic progenitor (PP), endocrine progenitor (EP), and endocrine cells (EC).
- DE definitive endoderm
- PP pancreatic progenitor
- EP endocrine progenitor
- EC endocrine cells
- B WT mouse ES cells were subjected to the 17-day differentiation protocol. Each lane represents a different condition at specific time points.
- RT-PCR analyses were performed to monitor the expression of pancreatic differentiation markers such as insulin- 1 (Insl), glucagon (Gcg), somatostatin (Sst), neurogenin-3 ( gn3), Pdxl and Soxl7, as well as the stem cell markers Nanog and Rexl.
- pancreatic differentiation markers such as insulin- 1 (Insl), glucagon (Gcg), somatostatin (Sst), neurogenin-3 ( gn3), Pdxl and Soxl7, as well as the stem cell markers Nanog and Rexl.
- HPRT1 amplification was used as a control housekeeping gene.
- Pancreas extracts from C57BL/6 WT mice were used as a positive control.
- Figure 2 Impact of RAR deletion on Pdxl expression through pancreatic endocrine differentiation process.
- A RT-PCR analysis confirming the suppression of RAR in KO ES cells. Analysis of Cyp26al, a RA-responsive gene, demonstrates the presence of RA signaling activity via other receptors in RAR KO cells. HPRT1 was used as a control housekeeping gene.
- FIG. 3 Expression of pancreatic differentiation markers in WT and RAR knockout (KO) ES cells.
- RT-PCR amplification of (A) Nanog, Ngn3, (B) Pax6, Isl-1, and (C) Insl, Gcg, and lapp mRNA was performed in both cell lines at 5, 11, 14, and 17 days of the differentiation protocol.
- FIG. 4 In vivo characterization of RAR deletion on islets of Langerhans functionality and glucose metabolism.
- FIG. 1 Serum retinol from mice on a high fat diet vs. control diet compared to the pancreas retinol and retinyl palmitate levels from mice on a high fat vs. control diet.
- the serum retinol levels are similar or a bit higher in the HF diet mice, but the pancreas retinol levels are much lower in the HF diet mice, showing vitamin A deficiency in the pancreas even in the presence of normal serum vitamin A.
- pancreas samples were fixed, embedded in paraffin, and sectioned. Then the tissue sections were stained with an antibody against 4-HNE (magnification, 200x). Sections from two mice/group were photographed and analyzed. The arrows indicate the pancreatic islets.
- AC261066 reduces oxidative stress in the pancreatic islets in mice on a high fat diet(HFD + AC261066).
- FIG. 8 AC261066 slightly reduces expression of c-peptide (marker of insulin secretion stress) in islets of HF fed mice.
- Figure 9 Gene expression of I S2, RARB2, CYP26A1 and LRAT in pancreatic tissue from wild type (wt) male C57/BL6 mice fed either chow control diet (Con), high fat (HF) diet, HF diet plus AC261066. Cyp26 and LRAT, no detectable signal. HPRT, loading control. RAR ⁇ 2 mR A levels were decreased by the high fat diet compared to the control diet (con), consistent with the vitamin A deficiency in the pancreas. AC261066 increased the RAR ⁇ 2 mRNA levels in the HF diet mice. [000109] Figure 10.
- FIG. 13 AC261066 diminished activation of hepatic stellate cells.
- Con chow control diet
- HF diet plus AC261066 or HF diet plus CD1530 RAR gamma agonist
- FIG. 15 Mouse serum triglyceride levels following the treatments indicated.
- Con control diet; HFD, high fat diet; HFD+AC, high fat diet+AC261066.
- AC261066 does not increase triglyceride levels at doses used.
- the HFD reduced retinyl esters, (retinyl palmitate), a form of storage of vitamin A in the liver, by greater than 90 % (left panel).
- the HFD also reduced retinol (vitamin A) levels by over 90 % to result in vitamin A deficiency in the liver.
- FIG. 1 4-hydroxynonenal (4-HNE), an indicator of oxidative stress, in the liver.
- the liver samples were fixed, embedded in paraffin, and sectioned. Then the tissue sections were stained with an antibody against 4-HNE (magnification, 200x). Sections from two mice/group were photographed and analyzed. These data show that AC261066 reduces oxidative stress and ROS (reactive oxygen species) in the livers of HF diet fed mice. Oxidative stress damages tissues.
- 4-HNE 4-hydroxynonenal
- hematoxylin and eosin stained kidney sections from wild type (wt) male C57/BL6 mice fed either a chow control diet (Con), high fat (HF) diet, HF diet plus AC261066 or HF diet plus CD1530 (RAR gamma agonist) for 4 months.
- CD1530 RAR gamma agonist
- FIG. 19 AC261066 diminished expression of the fibrogenic protein alpha- SMA.
- CFD Con fed diet
- HFD Oletyl esters
- retinol in the kidney, showing a vitamin A deficiency in kidney.
- FIG. 21 Gene Expression of Inflammatory Mediators in Kidneys of Control Normal Chow (13% fat) and HF- Fed Mice and RARs.
- Con chow control diet
- HF high fat
- AC261066 reduces the levels of TNF-alpha, a potent inflammatory protein, mRNA in high fat diet fed mice.
- AC261066 also restores RAR beta and LRAT mRNA levels, markers of functional vitamin A signaling, in the high fat diet fed mice, 4 months on the HFD. HPRT, loading control.
- FIG. 22 4-hydroxynonenal (4-HNE), an indicator of oxidative stress, in the kidneys.
- Figure 24 Gene Expression of vitamin A relevant genes in testes of Chow and HF-Fed Mice Gene expression of testes from wild type (wt) male C57/BL6 mice fed either a chow control diet (Con), high fat (HF) diet, HF diet plus AC261066. (Each number is data from one mouse, five mice total in each group.)
- the present invention relates to uses of vitamin A and retinoic acid receptor ⁇ ( ⁇ ) agonists in this regard.
- ES cells are pluripotent cells derived from the inner cell mass of blastocyst-stage (day 3.5) embryos (10, 1 1). Upon LIF removal, ES cells spontaneously differentiate into all three primary embryonic germ layers: endoderm, mesoderm, and ectoderm (10).
- endoderm endoderm
- mesoderm mesoderm
- ectoderm Several research groups have shown that the directed differentiation of ES cells along the endocrine pathway can be achieved by using a wide range of growth/differentiation factors, including retinoic acid (RA) treatment (12-17).
- RA retinoic acid
- Vitamin A metabolite all trans-retinoic acid (RA) acting through its cognate receptors, retinoic acid receptor (RAR) alpha, beta, gamma, possesses anti-obesity and anti-lipogenic properties through regulation of genes involved in energy metabolism and adipogenesis (75).
- RARP retinoic acid receptor ⁇
- vitamin A and RARP agonists are effective in treating and preventing high fat diet associated disease in pancreas, liver, kidney, testes and other organs. Furthermore, the inventors discovered that vitamin A and such (RARP) agonists can restore vitamin A signaling in organs that show vitamin A deficiencies.
- Vitamin A and these RARP agonists increase insulin signaling, decrease fat deposit, prevent inflammation, and decrease oxidative stress in various organs, including pancreas, liver, kidney and testes. They also decrease the level of alpha smooth muscle actin (a-SMA) but increase the level of lethicin:retinol acyltransferase (LRAT) and RARp.
- a-SMA alpha smooth muscle actin
- LRAT lethicin:retinol acyltransferase
- RARp lethicin:retinol acyltransferase
- vitamin A and these RAR agonists decrease the activation of hepatic stellate cells (HSCs) and the level of hepatic reactive oxygen species (ROS).
- RAR retinoic acid receptor-beta
- the retinoic acid receptor is a type of nuclear receptor that is activated by both all-trans retinoic acid and 9-cis retinoic acid.
- RAR retinoic acid receptor
- Each receptor isoform has several splice variants: two- for a, four- for ⁇ , and two- for ⁇ .
- RAR heterodimerizes with RXR and in the absence of ligand, the RAR/RXR dimer binds to hormone response elements known as retinoic acid response elements (RAREs) complexed with corepressor protein.
- RAREs retinoic acid response elements
- RARfi agonists include but are not limited to: AC261066, AC55649, LE135, Tazarotene, Adapalene, CD666, 9-cis-retinoic acid, BMS641 and TTNPB.
- AC261066 and AC55649 are highly-specific RAR agonists.
- the term "highly-specific RAR agonists" also include other agonists having a binding affinity similar to AC261066 or AC55649, e.g., at least 50% or greater, preferably 75% or greater, more preferably 90% or greater of the RAR binding affinity of AC261066 or AC55649.
- RAR agonists include the fluorinated alkoxythiazoles previously described (65), such as:
- the highly specific ⁇ agonist e.g., AC261066
- AC261066 can significantly diminish hepatic gene expression of pro-inflammatory mediators tumor necrosis factor-alpha (TNFa) and monocyte chemotactic protein- 1 (MCP-1).
- TNFa tumor necrosis factor-alpha
- MCP-1 monocyte chemotactic protein- 1
- subject means an animal, preferably a mammal, and most preferably a human.
- a subject may be a patient having a disease or disorder as discussed herein.
- vitamin A deficiency refers to a lack of vitamin A or a decreased level of vitamin in serum or an organ (e.g., pancreas, liver, kidney or testes) of an animal, e.g., human.
- the terms “decreasing” and “reducing” are used interchangeably to refer to a negative change in the level, activity or function of a molecule, cell or organ. It is meant that the particular level, activity or function is lower by about 25%, about 50%, about 75%, about 90%, about 1-fold, about 2-fold, about 5 fold, about 10-fold, about 25-fold, about 50-fold, or about 100 fold, or lower, when compared to a control.
- the terms “increasing”, “improving” and “enhancing” are used interchangeably to refer to a positive change in the level, activity or function of a molecule, cell or organ. It is meant that the particular level, activity or function is higher by about 25%, about 50%, about 75%, about 90%, about 1-fold, about 2-fold, about 5 fold, about 10-fold, about 25- fold, about 50-fold, or about 100 fold, or higher, when compared to a control.
- therapeutically effective and “therapeutic effect” refer to a benefit including, but not limited to, the treatment or amelioration of symptoms of a proliferative disorder discussed herein. It will be appreciated that the therapeutically effective amount or the amount of agent required to provide a therapeutic effect will vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated (e.g., nature of the severity of the condition to be treated, the particular inhibitor, the route of administration and the age, weight, general health, and response of the individual patient), which can be readily determined by a person of skill in the art. For example, an amount of vitamin A or an agonist of RARP is therapeutically effective if it is sufficient to effect the treatment or amelioration of symptoms of a disease discussed herein.
- clinical significant level is used herein to refer to a level of a side effect such as cardiovascular risk caused by the administration of a pharmaceutical composition (e.g., vitamin A or RARP agonist) that a physician treating the subject would consider to be significant.
- a pharmaceutical composition e.g., vitamin A or RARP agonist
- the term “comprises” means “includes, but is not limited to.”
- pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
- a pharmaceutically acceptable salt of vitamin A or agonist of ⁇ is utilized in pharmaceutical compositions, the salt preferably is derived from an inorganic or organic acid or base.
- suitable salts see, e.g., Berge et al, J. Pharm. Sci. 66: 1-19 (1977) wad Remington: The Science and Practice of Pharmacy, 20th Ed., ed. A. Gennaro, Lippincott Williams & Wilkins, 2000.
- pharmaceutically acceptable carrier is used herein to refer to a material that is compatible with a recipient subject, preferably a mammal, more preferably a human, and is suitable for delivering an active agent to the target site without terminating the activity of the agent.
- the toxicity or adverse effects, if any, associated with the carrier preferably are commensurate with a reasonable risk/benefit ratio for the intended use of the active agent.
- carrier is used interchangeably herein, and include any and all solvents, diluents, and other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- compositions of the invention can be manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, or emulsifying processes, among others.
- Compositions may be produced in various forms, including granules, precipitates, or particulates, powders, including freeze dried, rotary dried or spray dried powders, amorphous powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions.
- Formulations may optionally contain solvents, diluents, and other liquid vehicles, dispersion or suspension aids, surface active agents, pH modifiers, isotonic agents, thickening or emulsifying agents, stabilizers and preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- the vitamin A or agonist of RARP can be administered by any method known to one skilled in the art.
- vitamin A or agonist of RARP may be administered orally or parenterally.
- parenteral includes subcutaneous, intravenous, intramuscular, intra- articular, intra- synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
- the compositions are administered orally, intravenously, or subcutaneously.
- the formulations of the invention may be designed to be short- acting, fast-releasing, or long-acting.
- compounds can be administered in a local rather than systemic means, such as administration (e.g., by injection) at a tumor site.
- Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers.
- the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P. and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid are used in the preparation of injectables.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and g
- Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art.
- Combination therapies that comprise the combination of vitamin A and agonist of RARP of the present invention, and further with one or more other therapeutic agents can be used, for example, to: 1) enhance the therapeutic effect(s) of the methods of the present invention and/or the one or more other therapeutic agents; 2) reduce the side effects exhibited by the methods of the present invention and/or the one or more other therapeutic agents; and/or 3) reduce the effective dose of vitamin A or agonist of RARP of the present invention and/or the one or more other therapeutic agents.
- vitamin A or agonist of RARP depends upon a number of factors, including the nature of the severity of the condition to be treated, the route of administration and the age, weight, general health, and response of the individual subject.
- the suitable dose level is one that achieves this therapeutic response and also minimizes any side effects associated with the administration.
- vitamin A or agonist of RARP may be administered at an amount from about 30 mg to about 200 mg per day, e.g., about 50 mg to about 150 mg per day, about 50 to about 100 mg per day, about lOOmg to about 150 mg per day.
- Vitamin A or agonist of RARP may be administered in single or divided or multiple doses. It will be understood that a suitable dosage of vitamin A or agonist of RARP may be taken at any time of the day or night, with food or without food.
- the treatment period during which an agent is administered is then followed by a non-treatment period of a particular time duration, during which the therapeutic agents are not administered to the patient. This non-treatment period can then be followed by a series of subsequent treatment and non-treatment periods of the same or different frequencies for the same or different lengths of time.
- Pancreatic endocrine differentiation protocol A slightly modified version of the established protocols published by Borowiak (14) and D'Amour (15) was used to carry out differentiation of hormone expressing endocrine cells from mouse ESCs. Prior to differentiation, ESCs were seeded at 5x10 5 on 30 mm gelatin-coated plates. After overnight culture, cells were exposed to 250 nM BIO-Acetoxime (EMD Bioscience, San Diego, CA) + 50 ng/ml activin A (R&D Systems, Minneapolis, MN) in Advanced RPMI (GIBCO, Grand Island, NY) supplemented with IX L-Glu and 0.2% FBS (GIBCO) for 1 day, and then to activin A alone in the same media.
- BIO-Acetoxime EMD Bioscience, San Diego, CA
- activin A R&D Systems, Minneapolis, MN
- RT-PCR analysis Various markers for endodermal (day 5), pancreatic progenitor (day 11), endocrine progenitor (day 14) and endocrine (day 17) differentiation were analyzed by semiquantitative RT-PCR in Jl wild-type and RAR KO ESCs. Specific primers used and amplification conditions are listed in Table- 1. Primers were designed around introns whenever possible. Primers not designed around introns are shown in Table 1 with an asterisk. Total RNA extraction, semi-quantitative and quantitative PCR reactions were performed as previously described (18). Amplified PCR products were resolved on 1.5% agarose gels and visualized by staining with ethidium bromide. PCR bands were sequenced for verification of the correct amplicon. Quantitation of semi-quantitative gels was performed using ImageJ software (National Institutes of Health) from three experimental biological repeats.
- Phalloidin-TRITC (Millipore, FAK100, 1 : 1000, Billerica, MA) was used to stain the actin stress fiber network (F-actin). Nuclei were stained using DAPI contained in Vectashield® mounting medium for fluorescence (Vector labs, Burlingame, CA). Quantitation of C-peptide positive stained cells and islet surface area was performed using NIS- Elements Advanced Research software (Nikon).
- mice were used for this experiment as previously described (26). Briefly, mice were fasted for 15 hours overnight and a 50% dextrose solution (2g/kg body weight) was injected intraperitoneally. Blood glucose levels were measured from the tail vein at 0, 15, 30, 60, and 120 min using the One Touch Blood Glucose Monitoring System (LifeScan) (32).
- LifeScan One Touch Blood Glucose Monitoring System
- the endocrine differentiation protocol was selected because it included RA-treatment at day 7 and also showed expression of later stage endocrine markers using human ES cells (15).
- the D'Amour et al. (2006) pancreatic differentiation protocol was used with some slight modifications to generate pancreatic endocrine cells in culture through the use of specific growth factors ( Figure 1A).
- the first modification replaced Wnt3a with BIO-acetoxime (BIO).
- BIO BIO-acetoxime
- Wnt3a has been documented as being important for mesendoderm specification and BIO-acetoxime is a selective inhibitor of GSK-3 which indirectly acts as a Wnt3a agonist during cell differentiation (33, 34).
- nicotinamide was included during the last stage of differentiation because various published protocols included this reagent due to strong evidence for its efficacy in pancreatic differentiation (35, 36).
- Example 3 RARp knockout delays Pdxl expression in pancreatic endocrine differentiation
- Neurogenin-3 (Ngn3), a master transcription factor during onset of pancreatic endocrine lineages (39, 41, 43), displayed a phased induction pattern in WT cells but was not induced in RARP knockout ( Figure 3A).
- Paired-box 6 (Pax6) and Isletl (Isl-1) represent two important transcription factors in pancreatic islet cell differentiation, which are expressed from intermediate (“"mid””) to terminally differentiated (“"late””) stages (39, 40, 44, 45). While no difference were noted for Pax6 expression patterns, Isl-1 displayed a delayed expression peak in RARP KO cells as compared to WT (day-14 versus day-11) ( Figure 3B).
- Example 5 Deletion of RARP affects in vivo glucose metabolism and pancreatic islet functionality
- mice of both groups were fasted for 15 hours and blood glucose concentration was measured. While blood glucose levels in WT were normal (between 70 and 105 mg/dL) (49), RARP KO animals were found to be in a hypoglycemic state, slightly below normal levels (61 ⁇ 4.7 mg/dL) ( Figure 4B) (50).
- a time-course blood glucose reading experiment was performed which an intraperitonial injection of 2 mg/Kg (body weight) dextrose at time ""0"".
- Ngn3 the bHLH transcription factor Neurogenin3 (gn3) constitutes another key player in the commitment of endoderm to pancreatic precursors (40, 43, 47).
- Ngn3 is the earliest to be expressed in the endocrine differentiation pathway (40, 55). While no links between RA signaling and Ngn3 expression was reported in the literature, RARP KO cells displayed decreased levels of this transcription factor during pancreatic differentiation ( Figure 3). Thus, the impact of RARP deletion on Ngn3 could be indirect and involving the participation of intermediate factors.
- Pax6 and Isl-1 represent two major transcription factors having a role in endocrine lineage specification after bud formation (45, 56) Considering that Pax6 expression is not affected by RARP KO, and that the Isl-1 peak of expression is only delayed by such a deletion, it appears that absence of RA signaling through RARP is insufficient to completely abrogate endocrine differentiation, but may lead to significant defects in islet cell function.
- AC261066 (a RARp agonist from Tocris) solution.
- AC261066 was dissolved in dimethyl sulfoxide (DMSO) at the concentration of 1.5 mg/ml, and diluted in the drinking water for mice to the final concentration of 1.5 mg/100 ml.
- DMSO dimethyl sulfoxide
- mice were maintained on either a standard laboratory chow-fed diet (CFD) with 13 % kcal fat, (diet# 5053, Lab Diet, Inc, St. Louis, MO) or a high fat, western style diet (HFD) with 60% kcals from fat, (diet #58126, Lab Diet, Inc., St. Louis, MO) for 4 months.
- CFD chow-fed diet
- HFD high fat, western style diet
- the high fat diet group was further split into 2 groups for 3 months: i) high fat diet and the drinking water containing 1% DMSO; ii) high fat diet and the drinking water containing 1.5 mg/100 ml AC261066, a specific RARP agonist. Then mice were sacrificed by cervical dislocation. Blood and various tissue samples were harvested.
- PCR products were resolved on 2% agarose gels and visualized by staining with ehtidium bromide.
- Primers for gene expression used were as follows: RARP2, F: 5 '-TGGCATTGTTTGCACGCTGA-3 ' (SEQ ID No. 25), R: 5'- CCCCCCTTTGGCAAAGAATAGA-3 ' (SEQ ID No. 26), CYP26A1, F: 5'- CTTTATAAGGCCGCCCAGGTTAC-3 ' (SEQ ID No. 27), R: 5'- CCCGATCCGCAATTAAAGATGA-3 ' (SEQ ID No. 28), LRAT, F: 5'- TCTGGCATCTCTCCTACGCTG-3 ' (SEQ ID No.
- TGCTCGAGTGTGATGAAGG-3 ' (SEQ ID No. 33), R: 5 ' -TCCCTGTTGACTGGTCATT-3 ' (SEQ ID No. 34).
- pancreatic retinoids Analysis of pancreatic retinoids.
- the frozen pancreas tissue samples ( ⁇ 100 mg) were homogenized in 500 ⁇ cold phosphate-buffered saline (PBS).
- 100 ⁇ serum was diluted in cold PBS to total volume of 500 ⁇ .
- Retinyl acetate was added to each sample before the retinoid extraction for the calculation of extraction efficiency.
- the retinoids were extracted into 350 ⁇ of organic solution (acetonitrile/butanol, 50:50, v/v) in the dark.
- HPLC high performance liquid chromatography
- the sections were then incubated with secondary antibodies (1 :200, anti-mouse IgG from the M.O.M kit). As a negative control, sections were stained without incubation with primary antibodies. The signals were visualized based on a peroxidase detection mechanism with 3,3-diaminobenzidine (DAB) used as the substrate.
- DAB 3,3-diaminobenzidine
- the serum retinol levels are similar or a bit higher in the HF diet mice, but the pancreas retinol levels are much lower in the HF diet mice, showing vitamin A deficiency in the pancreas even in the presence of normal serum vitamin A (Fig 6).
- AC261066 decreases oxidative stress levels in the pancreas from HF-fed mice.
- High fat diet results in excessive reactive oxygen species (ROS) production that triggers inflammatory responses and subsequent injuries in many tissues. Therefore, we examined the levels of 4- hydroxynonenal (4-HNE), an ⁇ , ⁇ -unsaturated hydroxyalkenal that is produced by lipid peroxidation in cells during oxidative stress, and is a marker of oxidative stress caused by reactive oxygen species (ROS) in the pancreas.
- the pancreatic islets from HF-fed mice showed an increase in the 4-HNE levels compared to the chow-fed controls (Fig 7).
- the pancreatic islet samples from the high fat diet plus AC261066 group exhibited markedly lower 4-HNE staining intensity levels compared to HF-vehicle treated mice (Fig 7).
- AC261066 does diminish pancreatic islet insulin expression.
- Pancreatic islets stained for pro-insulin c-peptide (green) and glucagon (red) revealed that islets from HF and HF + AC261066 fed mice showed a marked increase in c-peptide staining compared to control diet controls (Fig 8).
- AC261066 slightly decreased c-peptide level in the HF diet mice.
- AC2621066 increased pancreatic mRNA expression of RARjJ in obese and vitamin A deficient mice. Consistent with our HPLC data demonstrating that pancreata tissue from HF- fed, obese mice had significantly decreased VA (vitamin A) levels, and significantly decreased mRNA levels of the VA responsive gene and VA signaling transcription factor, RAR . RAR ⁇ was decreased in pancreata of HF-fed obese mice compared to control diet fed mice (Fig 9).
- mRNA levels of RAR in pancreata HF-AC261066 treated mice were increased compared to HF-vehicle treated mice (Fig 9), and near levels observed in non-obese controls, suggesting that AC261066 can prevent or reverse the loss of VA signaling in VA depleted tissue. Similar findings in vitamin A deficient mice, Fig. 10.
- PCR products were resolved on 2% agarose gels and visualized by staining with ehtidium bromide.
- Primers for gene expression used were as follows: RARP2, F: 5 '-TGGCATTGTTTGCACGCTGA-3 ' (SEQ ID No. 25), R: 5'- CCCCCCTTTGGCAAAGAATAGA-3 ' (SEQ ID No. 26), CYP26A1, F: 5'- CTTTATAAGGCCGCCCAGGTTAC-3 ' (SEQ ID No. 27), R: 5'- CCCGATCCGCAATTAAAGATGA-3 ' (SEQ ID No. 28), LRAT, F: 5'- TCTGGCATCTCTCCTACGCTG-3 ' (SEQ ID No.
- R 5'- GCATTAGCTTCAGATTTACGGGT-3 ' (SEQ ID No. 38), HPRT, F:5'- TGCTCGAGTGTGATGAAGG-3 ' (SEQ ID No. 33), R: 5 ' -TCCCTGTTGACTGGTCATT-3 ' (SEQ ID No. 34).
- the sections were then incubated with secondary antibodies (1 :200, anti-mouse IgG from the M.O.M kit). As a negative control, sections were stained without incubation with primary antibodies. The signals were visualized based on a peroxidase detection mechanism with 3,3-diaminobenzidine (DAB) used as the substrate.
- DAB 3,3-diaminobenzidine
- AC261066 diminished hepatic steatosis.
- H and E staining of liver sections from treatment mice revealed that 4 months of a HF western style diet lead to increased hepatocyte lipid accumulation in HF-fed mice compared to CFD-fed mice (Fig 11).
- HF-fed mice treated with AC261066 showed marked decreased hepatocyte lipid infiltration compared to HF -vehicle treated mice (Fig 11).
- HF-fed mice treated with a RAR ⁇ ligand CD1530
- showed no decrease in hepatic lipid accumulation (Fig 1 1).
- AC261066 diminishes hepatic gene expression of alpha-SMA (alpha-smooth muscle actin) and SREBPlc. Consistent with our immunofluorescence microscopy showing that a- SMA protein is decreased in HF-AC261011 fed mice compared to HF -vehicle controls, hepatic mRNA levels of alpha-SMA were also decreased in livers of HF-AC26101 1 fed mice, but not in the livers of HF-CD1530 treated mice (Fig 12).
- AC261066 diminishes hepatic stellate cell (HSC) activation. Liver sections co-stained with the neutral lipid stain oil-red-o were in agreement with the H and E staining, demonstrating that HF-fed obese mice had ectopic accumulation of hepatic lipids (red) compared to CF controls (Fig 13). Livers of HF-AC261066-fed mice had marked diminished hepatic lipid accumulation compared to HF vehicle-fed mice (Fig 13). This effect was not observed in the livers of HF-fed mice treated with the CD1530 (RARy agonist).
- HSCs contribute to normal liver tissue repair processes, but unresolved HSC activation can lead to fibrotic lesion formation and the progression of steatosis to advanced NAFLD, such as non-alcoholic steatohepatitis (NASH).
- NAFLD non-alcoholic steatohepatitis
- To examine whether HF-fed obese mice exhibited evidence of increased activation of HSCs we stained liver sections with an a-SMA antibody. This analysis revealed the livers of HF-fed mice had increased a-SMA positive (green) staining compared to lean, CF controls. a-SMA positive areas tended to cluster in areas with hepatocyte lipid infiltration (Fig 13).
- livers of HF-fed-AC261066 treated mice had decreased intensity and regions of a-SMA positive staining (Fig 13). Moreover, clustering a-SMA in lipid positive (red) regions was not observed in liver of HF-AC261066 treated mice. Livers of HF-fed CD 1530 treated mice had no evidence decreased lipid accumulation or a-SMA expression intensity or patterns compared to HF fed-vehicle treated mice.
- AC261066 diminishes hepatic gene expression of pro-inflammatory mediators.
- NAFLD is typically associated with increased hepatic expression of pro-inflammatory cytokines and mediators such as the monocyte chemokine MCP-1 and the cytokine TNF-a.
- MCP-1 monocyte chemokine
- TNF-a cytokine TNF-a
- AC261066 does not elevate serum triglyceride levels.
- HF or HF + AC261066 feeding does not affect serum triglyceride levels compared CF controls. This suggests that AC261066 does not increase risk for cardiovascular disease and suggests that the liver lipid lowering effect of AC261066 does not correlate with increased hepatic lipid export.
- AC261066 partially reverses depletion of VA in livers of HF-fed Obese Mice.
- the liver stores approximately 80-90% of total body VA, therefore we conducted HPLC to determine the tissue levels of the major storage form of VA, retinyl-palmitate and of all-trans retinol in lean CF, HF and HF + AC261066 fed mice.
- Our analysis revealed that levels of retinyl-palmitate and retinol were decreased by 97% and 92% in livers in HF-fed, obese mice compared to lean, CF controls(Fig 16).
- Livers of mice fed HF + AC261066 and CD1530 also had significantly lowered retinyl palmitate and retinol compared to controls, however compared to HF-vehicle treated mice, we observed 55% higher levels of retinyl palmitate in the livers from HF-AC261066 fed mice, while retinyl palmitate levels in the liver of HF + CD1530 treated mice were almost 48% lower than livers from HF-vehicle treated mice (Fig 16). This suggests that longer administration of AC261066 to HF-fed obese mice may have significantly reversed HF-obesity driven liver VA depletion.
- Oxidative stress level is lower in the liver from the high fat diet plus AC261066 group than that in the high fat diet group.
- High fat diet results in excessive reactive oxygen species (ROS) production that triggers inflammatory responses and subsequent injuries in many tissues. Therefore, we examined the levels of 4- hydroxynonenal (4-HNE), an ⁇ , ⁇ -unsaturated hydroxyalkenal that is produced by lipid peroxidation in cells during oxidative stress, and is a marker of oxidative stress caused by reactive oxygen species (ROS) in the liver.
- the liver from the high fat diet group showed a large increase in the 4-HNE levels compared to the control fat diet group, and the liver samples from the high fat diet plus AC261066 group exhibited lower 4-HNE levels than those from the high fat diet group (Fig. 17).
- PCR products were resolved on 2% agarose gels and visualized by staining with ehtidium bromide.
- Primers for gene expression used were as follows: RARP2, F: 5 '-TGGCATTGTTTGCACGCTGA-3 ' (SEQ ID No. 25), R: 5'- CCCCCCTTTGGCAAAGAATAGA-3 ' (SEQ ID No. 26), CYP26A1, F: 5'- CTTTATAAGGCCGCCCAGGTTAC-3 ' (SEQ ID No. 27), R: 5'- CCCGATCCGCAATTAAAGATGA-3 ' (SEQ ID No. 28), TNF , F: 5'- CCTGTAGCCCACGTCGTAG-3 ' (SEQ ID No.
- R 5'- GGGAGTAGACAAGGTACAACCC-3 ' (SEQ ID No. 36), HPRT, F: 5'- TGCTCGAGTGTGATGAAGG-3 ' (SEQ ID No. 33), R: 5 ' -TCCCTGTTGACTGGTCATT-3 ' (SEQ ID No. 34).
- the sections were then incubated with secondary antibodies (1 :200, anti-mouse IgG from the M.O.M kit). As a negative control, sections were stained without incubation with primary antibodies. The signals were visualized based on a peroxidase detection mechanism with 3,3-diaminobenzidine (DAB) used as the substrate.
- DAB 3,3-diaminobenzidine
- AC261066 diminished renal lipid accumulation. H and E staining of kidney sections from treatment mice revealed that 4 months of a HF western style diet lead to increased renal lipid accumulation in HF-fed mice compared to CFD-fed mice (Fig 18). HF-fed mice treated with AC261066 showed markedly decreased renal lipid infiltration compared to HF -vehicle treated mice (Fig 18). HF-fed mice treated with a RAR ⁇ ligand (CD1530) showed no decrease in renal lipid accumulation (Fig 18).
- AC261066 diminishes renal expression of alpha-SMA. Kidney sections co-stained with the neutral lipid stain oil-red-o were in agreement with the H and E staining, demonstrating that HF-fed obese mice had ectopic accumulation of renal lipids (red) compared to CF controls (Fig 18). Kidneys of HF-AC261066-fed mice had marked diminished hepatic lipid accumulation compared to HF vehicle-fed mice (Fig 19). Alpha-SMA is required for normal kidney tissue repair processes, but unchecked alpha-SMA secretion can lead to fibrotic lesion formation and the progression of advanced renal disease.
- kidney sections stained with the neutral lipid stain oil-red-o showed marked increase in renal lipid droplets in kidneys of HF-fed mice compared to control fed mice.
- kidney sections from HF + AC261066 treated mice had comparably less oil red o positive areas.
- a-SMA (green) staining also revealed that kidneys of HF-fed mice had increased a-SMA positive areas compared to control fed mice (Fig 19). This increase in a-SMA positive areas was not observed in kidneys of HF + AC261066 treated mice.
- AC261066 diminishes kidney gene expression of pro-inflammatory mediators.
- Fibrosis is associated increased renal expression of pro-inflammatory cytokines and mediators.
- kidneys of HF-fed mice had evidence of inflammation marked by increased expression of inflammatory cytokines such as TNF-a.
- TNF-a inflammatory cytokines
- Our analysis revealed that mRNA levels of TNF-a were markedly elevated in livers of HF-fed mice, but not in livers of HF-fed AC261066 treated mice (Fig 21).
- Oxidative stress level as assessed by 4-hydroxynoneal (4-HNE) is lower in the kidneys from the high fat diet plus AC261066 group than that in the high fat diet group.
- High fat diet results in excessive reactive oxygen species (ROS) production that triggers inflammatory responses and subsequent injuries in many tissues. Therefore, we examined the levels of 4-hydroxynonenal (4-HNE), an ⁇ , ⁇ -unsaturated hydroxyalkenal that is produced by lipid peroxidation in cells during oxidative stress, and is a marker of oxidative stress caused by reactive oxygen species (ROS) in the kidneys
- 4-HNE 4-hydroxynonenal
- ROS reactive oxygen species
- PCR products were resolved on 2% agarose gels and visualized by staining with ehtidium bromide.
- Primers for gene expression used were as follows: RARP2, F: 5 '-TGGCATTGTTTGCACGCTGA-3 ' (SEQ ID No. 25), R: 5'- CCCCCCTTTGGCAAAGAATAGA-3 ' (SEQ ID No. 26), CYP26A1, F: 5'- CTTTATAAGGCCGCCCAGGTTAC-3 ' (SEQ ID No. 27), R: 5'- CCCGATCCGCAATTAAAGATGA-3 ' (SEQ ID No. 28), HPRT, F: 5'- TGCTCGAGTGTGATGAAGG-3 ' (SEQ ID No. 33), R: 5 ' -TCCCTGTTGACTGGTCATT-3 ' (SEQ ID No. 34).
- Each sample (100 ⁇ of the 350 ⁇ ) was loaded onto an analytical 5- ⁇ reverse phase C18 column (Vydac, Hesperia, CA) and eluted at a flow rate of 1.5 ml/min.
- Two mobile phase gradient systems were used.
- Retinoids were identified by HPLC based on two criteria: an exact match of the retention times of unknown peaks with those of authentic retinoid standards and identical UV light spectra (220-400 nm) of unknowns against spectra from authentic retinoid standards during HPLC by the use of a photodiode array detector. The amounts of retinoids were calculated from the areas under the peaks detected at the wave-length of 325 nm. The levels of retinol and retinyl esters were normalized to the tissue weight.
- Testes of HF-fed Mice have decreased expression of VA relevant genes expression.
- RARp agonist AC55649 is prepared in the same way and is used to treat mice as described in Examples 6-10.
- all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices and materials are herein described. All publications mentioned herein are hereby incorporated by reference in their entirety for the purpose of describing and disclosing the materials and methodologies that are reported in the publication which might be used in connection with the invention.
- Borowiak M Maehr R, Chen S, Chen AE, Tang W, Fox JL, Schreiber SL, Melton DA. Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell2009 Apr 3;4(4):348-58.
- Yamaguchi TP Takada S, Yoshikawa Y, Wu N, McMahon AP.
- T (Brachyury) is a direct target of Wnt3a during paraxial mesoderm specification. Genes & developmentl999 Dec 15;13(24):3185-90.
- Nicotinamide is a potent inducer of endocrine differentiation in cultured human fetal pancreatic cells. J Clin Invest 1993 Sep;92(3): 1459-66.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to pharmaceutical composition and methods of using vitamin A and/or RARB agonist for the treatment or prevention of diseases or conditions associated with high fat diet and/or vitamin deficiency. After smoking, high fat diet is said to be the second most lethal habit, causing 300,000 deaths each year in the U.S. alone. High fat diet leads to many health problems, including obesity, stroke, cancer, high blood pressure, diabetes, osteoarthritis, rheumatoid arthritis, multiple sclerosis, heart disease, and diseases in other organs such as liver and kidney.
Description
METHODS OF TREATING DISEASES ASSOCIATED WITH HIGH FAT DIET AND VITAMIN A DEFICIENCY USING RETINOIC ACID RECEPTOR AGONISTS
GOVERNMENT FUNDING
[0001] This invention was made with Government support under Grant Number R01 CA043796 awarded by National Institutes of Health (NCI) and Grant NumberROl DE10389 from the Dental and Craniofacial Institute. The United States Government has certain rights in the invention.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of United States Provisional Application Serial No.
61/754,438, filed January 18, 2013 which is incorporated herein in its entirety.
FIELD
[0003] The invention relates to the treatment and prevention of various diseases or conditions caused by fat accumulation or vitamin deficiency.
BACKGROUND
[0004] After smoking, high fat diet is said to be the second most lethal habit, causing 300,000 deaths each year in the U.S. alone. High fat diet leads to many health problems, including obesity, stroke, cancer, high blood pressure, diabetes, osteoarthritis, rheumatoid arthritis, multiple sclerosis, heart disease, and diseases in other organs such as liver and kidney.
[0005] Diabetes is a group of pancreatic diseases characterized by high blood glucose levels that result from defects in the body's ability to produce and/or use insulin. In 201 1 there were an estimated 366 million cases of diabetes worldwide, according to the International Diabetes Federation, and these cases are estimated to increase to 522 million by 2030 (1, 2). In the U.S. there were 23.7 million diagnosed cases, with an estimated healthcare cost of $ 113 billion (2, 3). Diabetes results when insulin production by pancreatic β-cells does not meet the metabolic demand of peripheral tissues such as liver, fat, and muscle (4). A reduction in β-cell number and function leads to hyperglycemia in both type I and type II diabetes (4). In type I diabetes, insulin- producing pancreatic β-cells lose self-tolerance and this gives rise to hyperglycemia (5). Each year in the United States there are over 30,000 new cases of type I diabetes diagnosed (6). Patients with type I diabetes can control their blood glucose level with insulin supplements (7). However, the differentiation of stem cells into pancreatic β-cells could be a long term, better solution (8-10).
[0006] Type II diabetes is more common. In type II diabetes the body does not use insulin properly, thus it is called insulin resistance. At first, the pancreas may make extra insulin to make up for it. But over time there won't be enough insulin to keep blood glucose at normal levels. Type II diabetes is an increasingly prevalent disease that due to a high frequency of complications leads to a significant reduction of life expectancy. Because of diabetes associated
microvascular complications, type II diabetes is currently the most frequent cause of adult-onset loss of vision, renal failure, and amputations in the industrialized world. In addition, the presence of type II diabetes is associated with a two to five fold increase in cardiovascular disease risk. After long duration of disease, most patients with type II diabetes will eventually fail on oral therapy and become insulin dependent with the necessity for daily injections and multiple daily glucose measurements.
[0007] A third type of diabetes, gestational diabetes, is developed by many women usually around the 24th week of pregnancy. Treatment for gestational diabetes aims to keep blood glucose levels equal to those of pregnant women who don't have gestational diabetes.
[0008] Some patients with diabetes can manage their conditions with healthy eating and exercise. Some will need to have prescribed medications and/or insulin to keep blood glucose levels. In addition, diabetes is a progressive disease. Even if medication is not required at first, it may be needed overtime.
[0009] Non-alcoholic fatty liver disease (NAFLD) is marked by lipid accumulation in hepatocytes (steatosis) without evidence of hepatitis or liver fibrosis (69, 70). NAFLD is a major risk factor for development of non-alcohol steatohepatitis (NASH) and hepatocellular carcinoma (71). Driven by rising rates of obesity, diabetes and insulin resistance, NAFLD is currently the most common form of liver disease in the United States with an estimated 55 million cases (69). At the current rate, NAFLD will reach epidemic proportions in the United States by 2030; yet no FDA approved pharmacological therapy exist for prevention or treatment of NAFLD (69).
[00010] Over the last decade, experimental animal and human data suggests that hepatic stellate cells (HSCs) are an important cellular target for development of pharmacological therapies for prevention or treatment of NAFLD spectrum liver diseases (73). HSCs are star-like cells that reside in the liver sinusoids whose main function are to store 80-90% of the total body vitamin A (VA) pool (74). During hepatic injury HSCs losing their VA storage capacity, trans-differentiate into myofibroblasts and orchestrate wound healing by secreting components of extra-cellular matrix including type 1 collagen (collal) and alpha-smooth muscle actin (a-SMA) (72, 73). During pathogenesis of unchecked NAFLD, HSCs proliferate and become highly fibrotic through hyper-secretion collal and a-SMA leading to liver scarring and an inflammation cascade that drives further hepatic fibrosis and liver damage (72,73).
[00011] Diabetes is the most common cause of kidney failure, accounting for nearly 44 percent of new cases. Even when diabetes is controlled, the disease can lead to Chronic Kidney Disease (CKD) and kidney failure. Nearly 24 million people in the United States have diabetes, and nearly 180,000 people are living with kidney failure as a result of diabetes. People with kidney failure undergo either dialysis, an artificial blood-cleaning process, or transplantation to receive a
healthy kidney from a donor. In 2005, care for patients with kidney failure cost the United States nearly $32 billion.
[00012] There is an unmet medical need for methods, medicaments and pharmaceutical compositions with regard to disease-modifying properties and with regard to reduction of high fat diet or vitamin A deficiency associated diseases while at the same time showing a good safety profile.
SUMMARY
[00013] This invention discloses pharmaceutical compositions and methods for treating and preventing diseases in pancreas, liver, kidney, testes, as well as other organs that are associated with high fat diet and/or vitamin A deficiency.
[00014] According to certain embodiments, the invention provides a method of treating or preventing a pancreatic disease in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR{5).
[00015] In certain embodiments, the pancreatic disease is associated with obesity.
[00016] In certain embodiments, the pancreatic disease is associated with a high fat diet.
[00017] In certain embodiments, the pancreatic disease is associated with vitamin A deficiency in the pancreas.
[00018] The pancreatic disease may be diabetes, which may be type I or type II diabetes, or gestational diabetes.
[00019] According to certain embodiments, the invention provides a method of increasing RARP level in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
[00020] In certain embodiments, RAR level is increased in an organ.
[00021] The organ may be pancreas, liver, kidney, or testes.
[00022] According to certain embodiments, the invention provides a method of treating or preventing the degeneration of pancreatic beta cells in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
[00023] According to certain embodiments, the invention provides a method of maintaining or improving the function of pancreatic beta cells in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
[00024] According to certain embodiments, the invention provides a method of maintaining or improving pancreatic insulin secretion in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
[00025] According to certain embodiments, the invention provides a method of maintaining or improving insulin sensitivity in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
[00026] According to certain embodiments, the invention provides a method of maintaining or improving the level of glucagon in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
[00027] According to certain embodiments, the invention provides a method of treating or preventing fat deposit of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
[00028] According to certain embodiments, the invention provides a method of treating or preventing inflammation of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
[00029] According to certain embodiments, the invention provides a method of decreasing the level of an inflammatory mediator in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
[00030] According to certain embodiments, the invention provides a method of decreasing oxidative stress in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
[00031] In certain embodiments, the production of the inflammatory mediator is decreased.
[00032] In certain embodiments, the secretion of the inflammatory mediator is decreased.
[00033] The inflammatory mediator may be monocyte chemotactic protein (mcp-1) or tumor necrosis factor alpha (tnf-d) according to certain embodiments.
[00034] In certain embodiments, the fat deposit, inflammation or oxidative stress is in an organ.
[00035] The organ may be pancreas, liver, kidney, or testes.
[00036] According to certain embodiments, the invention provides a method of treating or preventing a liver disease in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
[00037] In certain embodiments, the liver disease is associated with obesity.
[00038] In certain embodiments, the liver disease is associated with a high fat diet.
[00039] In certain embodiments, the liver disease is associated with vitamin A deficiency.
[00040] In certain embodiments, the liver disease is fatty liver disease (FLD), liver fibrosis, or hepatic steatosis.
[00041] In certain embodiments, the liver disease is non-alcoholic FLD (NAFLD), alcohol associated FLD, or non-alcoholic steatohepatitis (NASH).
[00042] In certain embodiments, the liver disease is associated with reduced vitamin A level in the liver.
[00043] According to certain embodiments, the invention provides a method of decreasing the activation of hepatic stellate cells (HSCs) in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
[00044] According to certain embodiments, the invention provides a method of decreasing the level of hepatic reactive oxygen species (ROS) in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
[00045] According to certain embodiments, the invention provides a method of decreasing the level of alpha smooth muscle actin (a-SMA) in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
[00046] According to certain embodiments, the invention provides a method of increasing the level of lethicin:retinol acyltransferase (LRAT) in the liver of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
[00047] According to certain embodiments, the invention provides a method of increasing the level of RAR in the liver of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
[00048] According to certain embodiments, the invention provides a method of decreasing the level of SRBPlc in the liver of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
[00049] In certain embodiments, the subject has a liver disease.
[00050] In certain embodiments, the liver disease is fatty liver disease (FLD), liver fibrosis, or hepatic steatosis.
[00051] In certain embodiments, the liver disease is non-alcoholic FLD (NAFLD), alcohol associated FLD, or non-alcoholic steatohepatitis (NASH).
[00052] In certain embodiments, the liver disease is associated with reduced vitamin A level in the liver.
[00053] In certain embodiments, the liver disease is associated with a pancreas disease.
[00054] According to certain embodiments, the invention provides a method of treating or preventing a kidney disease in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
[00055] In certain embodiments, the kidney disease is associated with obesity.
[00056] In certain embodiments, the kidney disease is associated with a high fat diet.
[00057] In certain embodiments, the kidney disease is kidney fibrosis.
[00058] In certain embodiments, the kidney disease is a chronic kidney disease.
[00059] In certain embodiments, the kidney disease is associated with a pancreatic disease.
[00060] In certain embodiments, the kidney disease is associated with a liver disease.
[00061] In certain embodiments, the kidney disease is associated with reduced vitamin A level in the kidney.
[00062] According to certain embodiments, the invention provides a method of increasing the level of lethicin:retinol acyltransferase (LRAT) in the kidney of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
[00063] According to certain embodiments, the invention provides a method of treating or preventing a disease associated with an organ-specific vitamin A deficiency in a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARp).
[00064] In certain embodiments, the organ-specific vitamin A deficiency is associated with obesity.
[00065] In certain embodiments, the organ-specific vitamin A deficiency is associated with a high fat diet.
[00066] In certain embodiments, the subject has a normal serum level of vitamin A or retinyl esters.
[00067] The organ may be pancreas, liver, or kidney.
[00068] According to certain embodiments, the invention provides a method of treating or preventing fibrosis in a subject comprising administering to the subject an agonist of retinoic acid receptor-beta (RAR ).
[00069] According to certain embodiments, the invention provides a method of decreasing the accumulation of fat in a subject comprising administering to the subject an agonist of retinoic acid receptor-beta (RAR ).
[00070] In certain embodiments, the fibrosis or accumulation of fat is in an organ.
[00071] The organ may pancreas, liver, kidney, or testes.
[00072] According to certain embodiments, the vitamin A or agonist of retinoic acid receptor-beta
(RAR ) is administered three times daily.
[00073] In certain embodiments, the vitamin A or agonist of retinoic acid receptor-beta (RAR ) is administered at an amount from 30-200 mg per day.
[00074] In certain embodiments, the vitamin A or agonist is administered at an amount from 50-
150 mg per day.
[00075] In certain embodiments, the vitamin A or agonist is administered at an amount from 50- 100 mg per day/
[00076] In certain embodiments, the vitamin A or agonist is administered at an amount from 100- 150 mg per day.
[00077] In certain embodiments, the vitamin A or agonist of retinoic acid receptor-beta (RAR ) is administered orally.
[00078] In certain embodiments, the vitamin A or agonist of retinoic acid receptor-beta (RAR ) is administered intravenously or subcutaneously.
[00079] In certain embodiments, the vitamin A or agonist of retinoic acid receptor-beta (RAR ) does not elevate serum triglyceride in the subject.
[00080] In certain embodiments, the vitamin A or agonist of retinoic acid receptor-beta (RAR ) does not increase cardiovascular risk in the subject.
[00081] In certain embodiments, a therapeutic effective amount of the vitamin A or agonist of
RAR is administered.
[00082] In certain embodiments, both vitamin A and an agonist of RARP are both administered to the subject.
[00083] In certain embodiments, vitamin A and an agonist of RARP are administered concomitantly.
[00084] In certain embodiments, vitamin A and an agonist of RARP are administered sequentially.
[00085] According to certain embodiments, the invention provides a pharmaceutical composition comprising vitamin A or an agonist of retinoic acid receptor-beta (RARP) or a pharmaceutically acceptable salt thereof at an amount from about 1 Omg to about 60 mg.
[00086] In certain embodiments, the amount of the vitamin A or agonist is from 15 mg to about 50 mg.
[00087] In certain embodiments, the amount of the vitamin A or agonist is from 15 mg to about 35 mg.
[00088] In certain embodiments, the amount of the vitamin A or agonist is from about 35 mg to about 50 mg.
[00089] In certain embodiments, the amount of the vitamin A or agonist is from about 30 mg to about 200 mg.
[00090] In certain embodiments, the amount of the vitamin A or agonist is from about 50 mg to about 150 mg.
[00091] In certain embodiments, the amount of the vitamin A or agonist is from about 50 mg to about 100 mg.
[00092] In certain embodiments, the amount of the vitamin A or agonist is from about 100 mg to about 150 mg.
[00093] According to certain embodiments, the invention provides a pharmaceutical composition comprising vitamin A or an agonist of retinoic acid receptor-beta (RARP) or a pharmaceutically acceptable salt thereof at a concentration from about 0.1 mg to about 10 mg per 100 ml.
[00094] In certain embodiments, the concentration is from about 0.5 mg to about 5 mg per 100 ml.
[00095] In certain embodiments, the concentration is from about 1 mg to about 2.5 mg per 100 ml.
[00096] In certain embodiments, the agonist is a highly specific ΡνΑΡνβ agonist.
[00097] In certain embodiments, the agonist is AC261066.
[00098] In certain embodiments, the agonist is AC55649.
[00099] In certain embodiments, the pharmaceutical composition comprises both vitamin A and an agonist of ΡνΑΡνβ.
BRIEF DESCRIPTION OF THE DRAWINGS
[000100] Figure 1: Pancreatic endocrine differentiation protocol and its impact on the molecular level. (A) Schematic representation of the endocrine differentiation protocol adapted from D'Amour et al. (2006) used on mouse ES cells. Briefly, embryonic stem (ES) cells are treated with different growth factors to successively differentiate into definitive endoderm (DE), pancreatic progenitor (PP), endocrine progenitor (EP), and endocrine cells (EC). (B) WT mouse ES cells were subjected to the 17-day differentiation protocol. Each lane represents a different condition at specific time points. RT-PCR analyses were performed to monitor the expression of pancreatic differentiation markers such as insulin- 1 (Insl), glucagon (Gcg), somatostatin (Sst), neurogenin-3 ( gn3), Pdxl and Soxl7, as well as the stem cell markers Nanog and Rexl. HPRT1 amplification was used as a control housekeeping gene. Pancreas extracts from C57BL/6 WT mice were used as a positive control.
[000101] Figure 2: Impact of RAR deletion on Pdxl expression through pancreatic endocrine differentiation process. (A) RT-PCR analysis confirming the suppression of RAR in KO ES cells. Analysis of Cyp26al, a RA-responsive gene, demonstrates the presence of RA signaling activity via other receptors in RAR KO cells. HPRT1 was used as a control housekeeping gene. (B) Indirect immunofluorescence staining for Pdxl (green) in WT and RAR KO, at 5, 11, 14, and 17 days in the absence (untreated) or in the presence (treated) of growth factors used in the differentiation protocol. Cells were counterstained using rhodamine-conjugated phalloidin, which binds to F-actin (red) and nuclei were stained with DAPI (blue) (Bars = 50μιη).
[000102] Figure 3: Expression of pancreatic differentiation markers in WT and RAR knockout (KO) ES cells. Transcript expression analyses of (A) early, (B) mid, and (C) late stage endocrine pancreatic differentiation markers in WT and RAR KO ES cells. RT-PCR amplification of (A) Nanog, Ngn3, (B) Pax6, Isl-1, and (C) Insl, Gcg, and lapp mRNA was performed in both cell lines at 5, 11, 14, and 17 days of the differentiation protocol. In each case, RAR expression was monitored in both cell lines and HPRT1 was used as a control housekeeping gene. Relative amounts, normalized to HPRT1 levels for each marker tested, are shown in histograms (n=3; *: p<0.05; **: p<0.0079; ***: p<0.0003).
[000103] Figure 4: In vivo characterization of RAR deletion on islets of Langerhans functionality and glucose metabolism. (A) Indirect immunofluorescence staining of C-peptide (green) and Glucagon (red) on C57BL/6 WT and RAR KO mouse pancreas tissue sections. Pancreatic islet-
corresponding regions were circled by dashed lines and nuclei were marked with DAPI (blue) (bars = 50μιη). Islet size were quantified per surface area units (cm2), with respect to high resolution micrographs, for each group and presented as histogram (n=6; **: p=0.031). Western blot analysis of C-peptide and Glucagon expression was performed on WT and ΡνΑΡνβ KO mouse pancreas protein extracts. Ins-1 cells were used as positive control for C-peptide expression, while immunodetection of actin was used as a loading control. (B) Blood glucose concentration (mg/dL) in WT and ΡνΑΡνβ null, knockout mice after 15 h fasting (left) (n>5; p=0.001 1). Blood glucose clearance (right) for WT (♦) and RAR{5 KO (■) mice was measured following a 2mg/kg dextrose i.p. injection. Relative blood glucose levels were assessed at 0, 15, 30, 45, 60, and 120 minutes post-injection (n>6; *: p=0.0137; **: p<0.0064; ***: p<0.0001).
[000104] Figure 5. Retinoid levels in mouse pancreas following the treatment indicated. Con fed diet (CFD) (n=5); HFD (n=5). Mice fed a high fat diet/obese mice have almost no retinoids in the pancreas compared to mice on a control, normal chow diet. They exhibit an organ specific vitamin A deficiency.
[000105] Figure 6. Serum retinol from mice on a high fat diet vs. control diet compared to the pancreas retinol and retinyl palmitate levels from mice on a high fat vs. control diet. The serum retinol levels are similar or a bit higher in the HF diet mice, but the pancreas retinol levels are much lower in the HF diet mice, showing vitamin A deficiency in the pancreas even in the presence of normal serum vitamin A.
[000106] Figure 7. 4-hydroxynonenal (4-HNE), an indicator of oxidative stress, in the pancreas.
The pancreas samples were fixed, embedded in paraffin, and sectioned. Then the tissue sections were stained with an antibody against 4-HNE (magnification, 200x). Sections from two mice/group were photographed and analyzed. The arrows indicate the pancreatic islets. AC261066 reduces oxidative stress in the pancreatic islets in mice on a high fat diet(HFD + AC261066).
[000107] Figure 8. AC261066 slightly reduces expression of c-peptide (marker of insulin secretion stress) in islets of HF fed mice. Representative immunofluorescence stained pancreatic sections from wild type (wt) male C57/BL6 mice fed either chow control diet (Con), high fat (HF) diet, HF diet plus AC261066 for 4 months. Con Diet (n=5); HF diet (n=5); HF Diet + AC261066 (n=5). Blue, nuclei of cells; red, glucagon; green, c-peptide.
[000108] Figure 9. Gene expression of I S2, RARB2, CYP26A1 and LRAT in pancreatic tissue from wild type (wt) male C57/BL6 mice fed either chow control diet (Con), high fat (HF) diet, HF diet plus AC261066. Cyp26 and LRAT, no detectable signal. HPRT, loading control. RAR β2 mR A levels were decreased by the high fat diet compared to the control diet (con), consistent with the vitamin A deficiency in the pancreas. AC261066 increased the RAR β2 mRNA levels in the HF diet mice.
[000109] Figure 10. Gene expression of RAR{52 in pancreatic tissue from LRAT -/- vitamin A sufficient mice (VAS, normal control diet), LRAT -/- vitamin A deficient (VAD) mice, and LRAT -/- vitamin A deficient (VAD) mice treated with AC261066 for 8 weeks. AC261066 increased the RARP2 mR A levels in vitamin A deficient mice (LRAT -/- on a VAD diet for 4 months.
[000110] Figure 11. AC261066 diminished hepatic steatosis. Representative hematoxylin
and eosin stained liver sections from wild type (wt) male C57/BL6 mice fed either a chow control diet (Con), high fat (HF) diet, HF diet plus AC261066 or HF diet plus CD 1530 (RAR gamma agonist) for 4 months. Con Diet (n=5); HF diet (n=5); HF Diet + AC261066 (n=5), or HF diet + CD1530 (RAR gamma agonist) (n=4).
[000111] Figure 12. Gene Expression in Livers of Control and HF-Fed Mice. Gene
expression of SREBPlc and a-SMA in livers from wild type (wt) male C57/BL6 mice fed either a chow control diet (Con), high fat (HF) diet, a HF diet plus AC261066 or HF diet plus CD 1530 (RAR gamma agonist) for 4 months . Con Diet (n=5); HF diet (n=5);
HF Diet + AC261066 (n=5), or HF diet + CD1530 (RAR gamma agonist) (n=4).
[000112] Figure 13. AC261066 diminished activation of hepatic stellate cells. Representative immunofluorescence and oil red o stained liver sections from wild type (wt) male C57/BL6 mice fed either a chow control diet (Con), high fat (HF) diet, HF diet plus AC261066 or HF diet plus CD 1530 (RAR gamma agonist) for 4 months. Control Diet (n=5); HF diet (n=5); HF Diet + AC261066 (n=5), or HF diet + CD1530 (RAR gamma agonist).
[000113] Figure 14. Gene Expression of Inflammatory Mediators in Livers of LF and HF-Fed Mice. Gene expression of MCP-1, TNF-alpha in livers from wild type (wt) male C57/BL6 mice fed either a chow control diet (Con), high fat (HF) diet, HF diet plus AC261066 or HF diet plus CD1530 (RAR gamma agonist) for 4. LF Diet (n=5); HF diet (n=5); HF Diet + AC261066 (n=5), or HF diet + CD1530 (RAR gamma agonist) (n=4). AC261066 decreases levels of inflammatory proteins MCP- 1 and TNF alpha in livers of HF diet fed mice.
[000114] Figure 15. Mouse serum triglyceride levels following the treatments indicated. Con diet (n=2); HFD (n=3); HFDAC (n=5). Con, control diet; HFD, high fat diet; HFD+AC, high fat diet+AC261066. AC261066 does not increase triglyceride levels at doses used.
[000115] Figure 16. Retinoid levels in mouse liver following the treatments indicated. Con fed diet (CFD) (n=5); HFD (n=5); HFD + AC261066 (n=5), HFD + CD1530 (n=4). High fat diet caused a state of vitamin A deficiency in liver and this is partially reversed by AC261066. Note that the y-axes in the left panel are different for CFD and HFD. The HFD reduced retinyl esters, (retinyl palmitate), a form of storage of vitamin A in the liver, by greater than 90 % (left panel). The HFD also reduced retinol (vitamin A) levels by over 90 % to result in vitamin A deficiency in the liver.
[000116] Figure 17. 4-hydroxynonenal (4-HNE), an indicator of oxidative stress, in the liver. The liver samples were fixed, embedded in paraffin, and sectioned. Then the tissue sections were stained with an antibody against 4-HNE (magnification, 200x). Sections from two mice/group were photographed and analyzed. These data show that AC261066 reduces oxidative stress and ROS (reactive oxygen species) in the livers of HF diet fed mice. Oxidative stress damages tissues.
[000117] Figure 18. AC261066 diminished renal lipid accumulation. Representative
hematoxylin and eosin stained kidney sections from wild type (wt) male C57/BL6 mice fed either a chow control diet (Con), high fat (HF) diet, HF diet plus AC261066 or HF diet plus CD1530 (RAR gamma agonist) for 4 months. Con Diet (n=5); HF diet (n=5);
HF Diet + AC261066 (n=5), or HF diet + CD 1530 (RAR gamma agonist) (n=4).
[000118] Figure 19. AC261066 diminished expression of the fibrogenic protein alpha- SMA. Representative immunofluorescence and oil red o stained kidney sections from wild type (wt) male C57/BL6 mice fed either a chow control diet (Con), high fat (HF) diet, or HF diet plus AC261066 for 4 months. Chow Diet (n=5); HF diet (n=5); HF Diet + AC261066 (n=5), or HF diet + CD1530 (RAR gamma agonist).
[000119] Figure 20. Retinoid levels in mouse kidney following the treatments indicated. Con fed diet (CFD) (Lean) (n=5) or HFD (Obese)(n=5). The high fat diet led to dramatic declines in retinyl esters (retinyl palmitate) and retinol in the kidney, showing a vitamin A deficiency in kidney.
[000120] Figure 21. Gene Expression of Inflammatory Mediators in Kidneys of Control Normal Chow (13% fat) and HF- Fed Mice and RARs. Gene expression of kidney from wild type (wt) male C57/BL6 mice fed either a chow control diet (Con), high fat (HF) diet, HF diet plus AC261066.. AC261066 reduces the levels of TNF-alpha, a potent inflammatory protein, mRNA in high fat diet fed mice. AC261066 also restores RAR beta and LRAT mRNA levels, markers of functional vitamin A signaling, in the high fat diet fed mice, 4 months on the HFD. HPRT, loading control.
[000121] Figure 22. 4-hydroxynonenal (4-HNE), an indicator of oxidative stress, in the kidneys.
The kidney samples were fixed, embedded in paraffin, and sectioned. Then the tissue sections were stained with an antibody against 4-HNE (magnification, 200x). Sections from two mice/group were photographed and analyzed. AC261066 reduces oxidative stress (ROS) in the kidneys of mice fed the HF diet.
[000122] Figure 23. Retinoid levels in mouse testes following the treatments indicated. Con fed diet (CFD) (n=5) or HFD (n=5). High fat diet results in partial vitamin A deficiency in the testes.
[000123] Figure 24. Gene Expression of vitamin A relevant genes in testes of Chow and HF-Fed Mice Gene expression of testes from wild type (wt) male C57/BL6 mice fed either a chow control diet (Con), high fat (HF) diet, HF diet plus AC261066. (Each number is data from one mouse, five mice total in each group.)
DETAILED DESCRIPTION
[000124] As discussed above, there remains a need to provide alternate therapies or management for a variety diseases associated with high fat diet and vitamin A deficiency. Accordingly, the present invention relates to uses of vitamin A and retinoic acid receptor β (ΡνΑΡνβ) agonists in this regard.
[000125] Mouse embryonic stem (ES) cells are pluripotent cells derived from the inner cell mass of blastocyst-stage (day 3.5) embryos (10, 1 1). Upon LIF removal, ES cells spontaneously differentiate into all three primary embryonic germ layers: endoderm, mesoderm, and ectoderm (10). Several research groups have shown that the directed differentiation of ES cells along the endocrine pathway can be achieved by using a wide range of growth/differentiation factors, including retinoic acid (RA) treatment (12-17).
[000126] Although the effects of RA on cells and tissues are known to occur through the activation of retinoic acid receptors (RARa, RAR , and RARy) and their isoforms (6, 18), the events occurring downstream of RA signaling that direct the differentiation of definitive endoderm into endocrine precursors are poorly understood (4, 5, 19).
[000127] A series of in vivo experiments, including some in Xenopus revealed, however, that RA signaling is crucial for endocrine pancreatic development (20). For instance, mice containing an inducible transgene for the dominant negative RARa403 mutant, used to ablate retinoic acid- dependent processes in vivo, lacked both a dorsal and ventral pancreas, and died at the neonatal stage (21). Impaired pancreatic islet development and repletion were also observed in vivo, in vitamin A deficiency models (22, 23). Moreover, a study of the developmental pathways involved during in vitro islet neogenesis revealed a 3-fold induction of RAR transcripts from ""adherent"" to ""expanded"" stages of endocrine differentiation (24). Another study, based on the role of CRABPl and RBP4 in pancreatic differentiation, corroborated the up-regulation of RAR in early differentiation (11). While previous studies suggested that RAR is essential to pancreas development, little is known about its functional role in pancreas formation and islet maintenance in adults (25, 26).
[000128] Vitamin A metabolite all trans-retinoic acid (RA) acting through its cognate receptors, retinoic acid receptor (RAR) alpha, beta, gamma, possesses anti-obesity and anti-lipogenic properties through regulation of genes involved in energy metabolism and adipogenesis (75).
[000129] Using animal models, the present inventors have discovered that retinoic acid receptor β (RARP) plays an important role in organ development, maintenance, and function. The
inventors discovered that vitamin A and RARP agonists increase RARP function and signaling; vitamin A and these RARP agonists also increase the level of RARp.
[000130] The present inventors also discovered that vitamin A and RARP agonists are effective in treating and preventing high fat diet associated disease in pancreas, liver, kidney, testes and other organs. Furthermore, the inventors discovered that vitamin A and such (RARP) agonists can restore vitamin A signaling in organs that show vitamin A deficiencies.
[000131] Vitamin A and these RARP agonists, according to the discovery of the present inventors, increase insulin signaling, decrease fat deposit, prevent inflammation, and decrease oxidative stress in various organs, including pancreas, liver, kidney and testes. They also decrease the level of alpha smooth muscle actin (a-SMA) but increase the level of lethicin:retinol acyltransferase (LRAT) and RARp. When used to treat liver diseases, vitamin A and these RAR agonists decrease the activation of hepatic stellate cells (HSCs) and the level of hepatic reactive oxygen species (ROS).
[000132] The present inventors discovered that vitamin A or agonists of retinoic acid receptor-beta (RAR ) do not elevate serum triglyceride or increase cardiovascular risk at a clinically significant level.
[000133] The retinoic acid receptor (RAR) is a type of nuclear receptor that is activated by both all-trans retinoic acid and 9-cis retinoic acid. There are three retinoic acid receptors (RAR), RARa, RAR , and RARy, encoded by the RARa, RARP, RARy genes, respectively. Each receptor isoform has several splice variants: two- for a, four- for β, and two- for γ.
[000134] RAR heterodimerizes with RXR and in the absence of ligand, the RAR/RXR dimer binds to hormone response elements known as retinoic acid response elements (RAREs) complexed with corepressor protein. Binding of agonist ligands to RAR results in dissociation of corepressor and recruitment of coactivator protein that, in turn, promotes transcription of the downstream target gene into mRNA and eventually protein.
[000135] Known RARfi agonists include but are not limited to: AC261066, AC55649, LE135, Tazarotene, Adapalene, CD666, 9-cis-retinoic acid, BMS641 and TTNPB. AC261066 and AC55649 are highly-specific RAR agonists. The term "highly-specific RAR agonists" also include other agonists having a binding affinity similar to AC261066 or AC55649, e.g., at least 50% or greater, preferably 75% or greater, more preferably 90% or greater of the RAR binding affinity of AC261066 or AC55649.
[000138] 4'-Octyl-[l, l'-biphenyl]-4-carboxylic acid (65), Adapalene (67), BMS-231973, BMS- 228987, BMS-276393, BMS-209641 (66), BMS-189453 { 4-[(lE)-2-(5,6-Dihydro-5,5-dimethyl- 8-phenyl-2-naphthalenyl)ethenyl]-benzoic acid} (68), CD2019 (6-[4-methoxy-3-(l- methylcyclohexyl)phenyl]naphthalene-2-carboxylic acid), compounds described in WO2008/064136 and WO2007009083 and tazarotene (ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H- 1 -benzothiopyran-6-yl)ethynyl] pyridine-3-carboxylate).
[000143] CD666:
[000144] 9-cis-retinoic acid:
[000145] BMS641 :
[000146] TTNPB:
[000147] The highly specific ΡνΑΡνβ agonist, e.g., AC261066, can prevent hepatic steatosis and activation of HSCs, marked by decreased expression of a-SMA. AC261066 can significantly diminish hepatic gene expression of pro-inflammatory mediators tumor necrosis factor-alpha (TNFa) and monocyte chemotactic protein- 1 (MCP-1).
[000148] As used herein, the term "subject" means an animal, preferably a mammal, and most preferably a human. A subject may be a patient having a disease or disorder as discussed herein.
[000149] As used herein, the term "vitamin A deficiency" refers to a lack of vitamin A or a decreased level of vitamin in serum or an organ (e.g., pancreas, liver, kidney or testes) of an animal, e.g., human.
[000150] As used herein, the terms "decreasing" and "reducing" are used interchangeably to refer to a negative change in the level, activity or function of a molecule, cell or organ. It is meant that the particular level, activity or function is lower by about 25%, about 50%, about 75%, about 90%, about 1-fold, about 2-fold, about 5 fold, about 10-fold, about 25-fold, about 50-fold, or about 100 fold, or lower, when compared to a control.
[000151] As used herein, the terms "increasing", "improving" and "enhancing" are used interchangeably to refer to a positive change in the level, activity or function of a molecule, cell or organ. It is meant that the particular level, activity or function is higher by about 25%, about 50%, about 75%, about 90%, about 1-fold, about 2-fold, about 5 fold, about 10-fold, about 25- fold, about 50-fold, or about 100 fold, or higher, when compared to a control.
[000152] The expressions "therapeutically effective" and "therapeutic effect" refer to a benefit including, but not limited to, the treatment or amelioration of symptoms of a proliferative disorder discussed herein. It will be appreciated that the therapeutically effective amount or the amount of agent required to provide a therapeutic effect will vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated (e.g., nature of the severity of the condition to be treated, the particular inhibitor, the route of administration and the age, weight, general health, and response of the individual patient), which can be readily determined by a person of skill in the art. For example, an amount of vitamin A or an agonist of RARP is therapeutically effective if it is sufficient to effect the treatment or amelioration of symptoms of a disease discussed herein.
[000153] The term "clinically significant level" is used herein to refer to a level of a side effect such as cardiovascular risk caused by the administration of a pharmaceutical composition (e.g., vitamin A or RARP agonist) that a physician treating the subject would consider to be significant.
[000154] The term "about" is used herein to mean approximately, in the region of, roughly, or around. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 30%, preferably 20%, more preferably 10%.
[000155] As used herein, the term "comprises" means "includes, but is not limited to."
[000156] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
[000157] If a pharmaceutically acceptable salt of vitamin A or agonist of ΡνΑΡνβ is utilized in pharmaceutical compositions, the salt preferably is derived from an inorganic or organic acid or base. For reviews of suitable salts, see, e.g., Berge et al, J. Pharm. Sci. 66: 1-19 (1977) wad Remington: The Science and Practice of Pharmacy, 20th Ed., ed. A. Gennaro, Lippincott Williams & Wilkins, 2000.
[000158] The term "pharmaceutically acceptable carrier" is used herein to refer to a material that is compatible with a recipient subject, preferably a mammal, more preferably a human, and is suitable for delivering an active agent to the target site without terminating the activity of the agent. The toxicity or adverse effects, if any, associated with the carrier preferably are commensurate with a reasonable risk/benefit ratio for the intended use of the active agent.
[000159] The term "carrier" is used interchangeably herein, and include any and all solvents, diluents, and other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington: The Science and Practice of Pharmacy, 20th Ed. , ed. A. Gennaro, Lippincott Williams & Wilkins, 2000 discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof.
[000160] The pharmaceutical compositions of the invention can be manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, or emulsifying processes, among others. Compositions may be produced in various forms, including granules, precipitates, or particulates, powders, including freeze dried, rotary dried or spray dried powders, amorphous powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions. Formulations may optionally contain solvents, diluents, and other liquid vehicles, dispersion or suspension aids, surface active agents, pH modifiers, isotonic agents, thickening or emulsifying agents, stabilizers and preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
[000161] The vitamin A or agonist of RARP can be administered by any method known to one skilled in the art. For example, vitamin A or agonist of RARP may be administered orally or parenterally.
[000162] The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra- articular, intra- synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally,
intravenously, or subcutaneously. The formulations of the invention may be designed to be short- acting, fast-releasing, or long-acting. Still further, compounds can be administered in a local rather than systemic means, such as administration (e.g., by injection) at a tumor site.
[000163] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[000164] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
[000165] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents such as phosphates or carbonates.
[000166] Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art.
[000167] Combination therapies that comprise the combination of vitamin A and agonist of RARP of the present invention, and further with one or more other therapeutic agents can be used, for example, to: 1) enhance the therapeutic effect(s) of the methods of the present invention and/or the one or more other therapeutic agents; 2) reduce the side effects exhibited by the methods of the present invention and/or the one or more other therapeutic agents; and/or 3) reduce the effective dose of vitamin A or agonist of RARP of the present invention and/or the one or more other therapeutic agents.
[000168] The amount or suitable dosage of vitamin A or agonist of RARP depends upon a number of factors, including the nature of the severity of the condition to be treated, the route of administration and the age, weight, general health, and response of the individual subject. In certain embodiments, the suitable dose level is one that achieves this therapeutic response and also minimizes any side effects associated with the administration. For example, vitamin A or agonist of RARP may be administered at an amount from about 30 mg to about 200 mg per day, e.g., about 50 mg to about 150 mg per day, about 50 to about 100 mg per day, about lOOmg to about 150 mg per day.
[000169] Vitamin A or agonist of RARP may be administered in single or divided or multiple doses. It will be understood that a suitable dosage of vitamin A or agonist of RARP may be taken at any time of the day or night, with food or without food. In some embodiments, the treatment period during which an agent is administered is then followed by a non-treatment period of a particular time duration, during which the therapeutic agents are not administered to the patient. This non-treatment period can then be followed by a series of subsequent treatment and non-treatment periods of the same or different frequencies for the same or different lengths of time.
[000170] In the following description, reference is made to the accompanying drawings that form a part hereof, and in which is shown by way of illustration specific embodiments which may be practiced. These embodiments are described in detail to enable those skilled in the art to practice the invention, and it is to be understood that other embodiments may be utilized and that logical changes may be made without departing from the scope of the present invention. The following description of example embodiments is, therefore, not to be taken in a limited sense, and the scope of the present invention is defined by the appended claims.
EXAMPLES
[000171] The present description is further illustrated by the following examples, which should not be construed as limiting in any way. The contents of all cited references (including literature references, issued patents, published patent applications as cited throughout this application) are hereby expressly incorporated by reference.
Example 1 - Materials and Methods
[000172] Cell Culture and Isolation of RARp Homozygous ES Cell Line. Mouse Jl wild-type ES cells were cultured as described previously (27). C57BL/6 ΡνΑΡνβ heterozygous mice were provided by Dr. Pierre Chambon (Strasbourg-Cedex, France) (26). Homozygous ΡνΑΡνβ-null mice were obtained following mating of ΡνΑΡνβ heterozygous mice. Blastocysts were harvested on day E3.5 and individually cultured on ES cell medium as previously described (28).
[000173] Pancreatic endocrine differentiation protocol. A slightly modified version of the established protocols published by Borowiak (14) and D'Amour (15) was used to carry out differentiation of hormone expressing endocrine cells from mouse ESCs. Prior to differentiation, ESCs were seeded at 5x105 on 30 mm gelatin-coated plates. After overnight culture, cells were exposed to 250 nM BIO-Acetoxime (EMD Bioscience, San Diego, CA) + 50 ng/ml activin A (R&D Systems, Minneapolis, MN) in Advanced RPMI (GIBCO, Grand Island, NY) supplemented with IX L-Glu and 0.2% FBS (GIBCO) for 1 day, and then to activin A alone in the same media. Cells were then cultured for 4 days to induce endoderm differentiation. For pancreatic progenitor induction, the cells were transferred to 50 ng/ml FGF10 (R&D Systems), 7.5 μΜ cyclopamine (Calbiochem, San Diego, CA) in DMEM supplemented with IX L-Glu, IX Pen/Strep, and IX B27 (Invitrogen, Grand Island, NY) for 2 days. At day 7, cells were transferred to FGF10, cyclopamine and 2 μΜ all-trans RA (Sigma, St. Louis, MO) in DMEM supplemented with IX L-Glu, IX Pen/Strep, and IX B27 (Invitrogen) for 4 days. At day 11, cells were cultured in the presence of DMEM supplemented with IX L-Glu, IX Pen/Strep, and IX B27 for 3 days. At day 14, CMRL (Invitrogen) medium was added and supplemented with IX L-Glu, IX Pen/Strep, IX B27, 50 ng/ml IGF-1 (R&D Systems), 50 ng/ml HGF (R&D Systems), and 10 mM nicotinamide (Sigma) for 3 more days. All stock compounds were made in either PBS or ethanol.
[000174] RT- PCR analysis. Various markers for endodermal (day 5), pancreatic progenitor (day 11), endocrine progenitor (day 14) and endocrine (day 17) differentiation were analyzed by semiquantitative RT-PCR in Jl wild-type and RAR KO ESCs. Specific primers used and amplification conditions are listed in Table- 1. Primers were designed around introns whenever possible. Primers not designed around introns are shown in Table 1 with an asterisk. Total RNA extraction, semi-quantitative and quantitative PCR reactions were performed as previously described (18). Amplified PCR products were resolved on 1.5% agarose gels and visualized by staining with ethidium bromide. PCR bands were sequenced for verification of the correct amplicon. Quantitation of semi-quantitative gels was performed using ImageJ software (National Institutes of Health) from three experimental biological repeats.
[000175] Table 1: Primer sequences used for RT-PCR
[000176] Indirect Immunofluorescence. Immunofluorescence assays on cells and tissue sections were performed as previously described (29). Briefly, differentiated samples were fixed using 4% (w/v) paraformaldehyde and membrane permeabilization (for cells only) was done with 0.3% (w/v) Triton-X 100 (Sigma). Unspecific sites were blocked using 2% BSA for 30 min prior to incubation with rabbit polyclonal anti-PDXl (Millipore, 06-1379, 1: 1000), rabbit anti-C-Peptide (Cell Signaling, 4593, 1 :500, Danvers, MA) and mouse monoclonal anti-Glucagon (Abeam, abl0988, 1 :200) primary antibodies. Phalloidin-TRITC (Millipore, FAK100, 1 : 1000, Billerica, MA) was used to stain the actin stress fiber network (F-actin). Nuclei were stained using DAPI contained in Vectashield® mounting medium for fluorescence (Vector labs, Burlingame, CA). Quantitation of C-peptide positive stained cells and islet surface area was performed using NIS- Elements Advanced Research software (Nikon).
[000177] Western blot analysis. Proteins were extracted from mouse pancreas, separated by SDS- PAGE, and transferred onto nitrocellulose membranes as previously described (30, 31). Membranes were blocked in PBS containing 5% skim milk and 0.1% TWEEN 20 (BioRad, Hercules, CA). Rabbit anti-C-Peptide (Cell Signaling, 4593, 1 :500), mouse monoclonal anti- Glucagon (Abeam, abl0988, 1 :500) and anti-actin (Millipore, MAB1501, 1:2000) primary antibodies were incubated with membranes overnight at 4°C.
[000178] Mouse Blood Glucose Assays. C57BL/6 WT and RAR KO mice were used for this experiment as previously described (26). Briefly, mice were fasted for 15 hours overnight and a
50% dextrose solution (2g/kg body weight) was injected intraperitoneally. Blood glucose levels were measured from the tail vein at 0, 15, 30, 60, and 120 min using the One Touch Blood Glucose Monitoring System (LifeScan) (32).
[000179] Statistical analysis. All experiments were performed at least 3 times (n>3) using independent biological triplicates. Results were presented as means ± SEM. All statistical tests were performed using GraphPad InStat software version 3.10. A p-value of <0.05 indicated statistical significance.
Example 2 - Pancreatic Differentiation and Assessment of Pancreatic Markers in WT mouse ES cells
[000180] The endocrine differentiation protocol was selected because it included RA-treatment at day 7 and also showed expression of later stage endocrine markers using human ES cells (15). The D'Amour et al. (2006) pancreatic differentiation protocol was used with some slight modifications to generate pancreatic endocrine cells in culture through the use of specific growth factors (Figure 1A). The first modification replaced Wnt3a with BIO-acetoxime (BIO). Wnt3a has been documented as being important for mesendoderm specification and BIO-acetoxime is a selective inhibitor of GSK-3 which indirectly acts as a Wnt3a agonist during cell differentiation (33, 34). Second, nicotinamide was included during the last stage of differentiation because various published protocols included this reagent due to strong evidence for its efficacy in pancreatic differentiation (35, 36).
[000181] To characterize the impact of the differentiation protocol on pancreatic endocrine specification in WT ES cells, cellular extracts were harvested at various time points during the procedure (Figure IB). The mRNA levels of various differentiation markers were assessed by RT-PCR for the different experimental conditions. LIF withdrawal combined with the addition of BIO and Activin A to the culture system caused a drastic decrease in the levels of ES cell markers Nanog and Rexl (Figure IB, lane 6) compared to untreated and RA-treated ES cells (Figure IB, lanes 1 to 4). Such a phenomenon was observed throughout the subsequent phases of the differentiation protocol (Figure IB, lanes 7 to 12). While robust expression of glucagon, a functional marker of a-cells (37), was observed by day-14 (Figure IB, lane 8), somatostatin, a hormone secreted by δ-cells (37), was detectable as early as day-5 (Figure IB, lane 6). Insulin-1 (β-cell marker)(37) was detected by day- 1 1 of the differentiation protocol but its expression fluctuated depending on the uses of HGF, IGF1, or both factors together during the endocrine cell differentiation stage (Figure IB, lanes 9 to 1 1). The most consistent expression of all 3 pancreatic endocrine differentiation markers tested was observed by combining HGF and IGF 1 with nicotinamide, from day-14 to 17 (Figure IB, lane 12). Even though keeping ES cells in culture, at confluence and in absence of LIF for 17 days, caused a decrease in Nanog and Rexl
expression, such conditions failed to induce any of the differentiation markers tested (Figure IB, lane 5).
[000182] These observations confirm the conversion of ES cells to endocrine cells able to express pancreatic hormone-encoding genes, according to a method described previously (15). Such a biological model represents a powerful tool to investigate the role of RARP at specific stages of pancreatic endocrine differentiation.
Example 3 - RARp knockout delays Pdxl expression in pancreatic endocrine differentiation
[000183] As previously mentioned, the RA signaling, including the participation of RAR , was suggested to be crucial for the onset of pancreatic endocrine differentiation (11, 20, 21, 24). In order to study the specific role of RAR in such a process, WT and RAR KO mouse ES cells were subjected to the endocrine differentiation protocol described above. RT-PCR analysis confirmed the absence of RARP transcript in KO cells (Figure 2A). The RARP2 isoform, like Cyp26al, represents a RA-inducible gene (38). This explains why stronger RARP signal was observed in the presence of RA, in WT cells compared to untreated ones (Figure 2A). RA- dependent Cyp26al expression was observed in both WT and RARP KO ES cells, suggesting that KO cells are still responding to RA stimuli (Figure 2A). Using this model of RARP deletion, the inventors sought to determine the impact of such a retinoid receptor on the expression of Pdxl, which consists in a master regulator of pancreatic cell fate (39-41).
[000184] WT and RARP KO ES cells were differentiated into pancreatic endocrine cells, as described in Figure 1, and indirect immunofluorescence staining for Pdxl was performed at the different stages of the protocol (Figure 2B). Pdxl expression was observed in WT differentiating cells by day-5, and was still present at all the other stages tested in a heterogeneous pattern (Figure 2B). In contrast, Pdxl protein was absent from nuclei of differencing cells at day-5 and 11, and was only detected by day- 14 of the protocol in RARP null cells (Figure 2B).
[000185] These observations suggest that the absence of RARP in this cell culture system undergoing pancreatic differentiation engenders a delay in the induction of Pdxl, which could potentially affect subsequent key steps of endocrine specialization.
Example 4 - Absence of RAR expression impairs the global pancreatic endocrine differentiation process
[000186] Considering the finding that RARP deletion in ES cells delays the expression of Pdxl during their specialization into pancreatic endocrine cells, the inventors decided to further investigate the impact of such a phenomenon on early, intermediate, and late molecular genetic events throughout the differentiation process. As reported in many studies on reprogramming, decreased expression of pluripotency factors, including Nanog, in ES cells is essential for proper differentiation (42). Nanog levels were previously shown to decrease around day-5 during the pancreatic endocrine differentiation protocol (Figure IB). A comparison of Nanog transcript
levels in WT and RARP KO differentiating cells, showed a sustained expression of this pluripotency factor in KO cells while it is severely repressed in WT controls (Figure 3A). On the other hand, the expression of Neurogenin-3 (Ngn3), a master transcription factor during onset of pancreatic endocrine lineages (39, 41, 43), displayed a phased induction pattern in WT cells but was not induced in RARP knockout (Figure 3A).
[000187] Like Ngn3, Paired-box 6 (Pax6) and Isletl (Isl-1) represent two important transcription factors in pancreatic islet cell differentiation, which are expressed from intermediate (""mid"") to terminally differentiated (""late"") stages (39, 40, 44, 45). While no difference were noted for Pax6 expression patterns, Isl-1 displayed a delayed expression peak in RARP KO cells as compared to WT (day-14 versus day-11) (Figure 3B).
[000188] Finally, the expression of different functional endocrine differentiation markers such as, glucagon (Gcg; a-cells), insulin- 1 (Insl ; β-cells) and islet amyloid polypeptide (IAPP; β-cells) was analyzed in RARP KO and WT differentiating cells (15, 46, 47) (Figure 3C). In all cases, RARP KO cells showed impaired expression of those functional markers as compared to WT (Figure 3C). Specifically, by day-17 Gcg, Insl, and Iapp respectively presented ~5-fold (p=0.04), ~120-fold (p=0.013), and ~7-fold (p=0.0002) increases in WT differentiated cells as compared to RARP KO (Figure 3C). Somatostatin (Sst), a functional marker of δ-cells (37) also displayed a decreased expression in RARP deficient cells (not shown).
[000189] Taken together, these observations show that RARP and retinoid signaling play a central role in pancreatic endocrine differentiation by regulating the expression of certain master genes at early and intermediate stages of the specialization process, which as a result impairs the expression of functional markers of pancreatic islet cells.
Example 5 - Deletion of RARP affects in vivo glucose metabolism and pancreatic islet functionality
[000190] The tissue culture system used to study diverse steps of pancreatic endocrine differentiation provided important insights about the role played by RARP in such a physiological process. Specifically, the absence of RARP expression leads to decreased or delayed expression of crucial transcription factors involved in islet cell differentiation, as well as decreased expression of functional differentiation markers (Figure 2 and 3). Thus, the inventors sought to validate the relevance of this finding in an in vivo model. A classical KO of both RARP alleles in mice, generated and characterized by Ghyselinck et al. (26), was used to study the impact of such a deletion on pancreatic endocrine functions. By extracting pancreas from WT and RARP-deficient mice, and performing indirect immunofluorescence staining for C- peptide, a by-product of insulin biosynthesis (48), and glucagon, the inventors observed a decrease (~75%, p < 0.0001) in the size of KO mice islets as compared to WT (Figure 4A).
Western blot analysis confirmed the decrease in C-peptide and glucagon expression in RARP KO mice pancreas extracts as compared to WT controls (Figure 4A). These observations demonstrate that RARP KO mice display decreased pancreatic endocrine islet cell production and/or maintenance, which could have major, deleterious effects on glucose metabolism.
[000191] To assess the systemic effects of RARP deletion on reduced insulin and glucagon- producing cells, mice of both groups were fasted for 15 hours and blood glucose concentration was measured. While blood glucose levels in WT were normal (between 70 and 105 mg/dL) (49), RARP KO animals were found to be in a hypoglycemic state, slightly below normal levels (61 ±4.7 mg/dL) (Figure 4B) (50). In order to test the functionality of P-cells in both mice groups, a time-course blood glucose reading experiment was performed which an intraperitonial injection of 2 mg/Kg (body weight) dextrose at time ""0"". Then, blood glucose clearance was monitored at 0, 15, 30, 45, 60, and 120 minutes in WT and RARP KO mice. We observed that blood glucose was metabolized faster in WT mice, as compared to KO (Figure 4B). Moreover, the average blood glucose levels in RARP KO mice 120 min after the dextrose injection was significantly higher (~30%, p=0.014) than in WT group, suggesting a lower glucose tolerance in animals lacking such a retinoid receptor (Figure 4B).
[000192] As described in the Examples, by using an ES cell-based directed differentiation system (Examples 2-4 ) and an in vivo gene knockout model (Example 5), the inventors demonstrated the crucial role for RARP in proper pancreatic endocrine cell differentiation. In both cases, the absence of RARP led to a decrease in terminal differentiation and functional markers, such as insulin and glucagon production. In mice, RARP deletion resulted in impaired glucose metabolism, characterized by hypoglycemia and glucose intolerance. Taken together, these findings indicate that reduced RARP and retinoic acid signaling are key factors in glucose metabolism disorders, such as diabetes mellitus type I and II. Hence, the administration of agonists of the RARP receptor can prevent or treat such disorders.
[000193] The study described in Example 2 leads to the conclusion that Pdxl expression, during the pancreatic differentiation process, was delayed in the absence of RARP (Figure-2). Such a transcription factor represents a key player in the early determination of pancreatic progenitors and bud expension (39, 40, 51, 52). A previous study reported that RA directly induces Pdxl expression in ES cells (51). Strengthening such a statement, ChlP-chip analyses performed on F9 teratocarcinoma cells revealed the presence of a putative retinoic acid response element (RARE) located at ~3 kb upstream of the transcription start site of Pdxl (not shown). That Pdxl expression is delayed but not fully suppressed in RARP-null ES cells opens a door on possible compensatory mechanisms exerted by other RARs. It has been previously noted that RARP transcript levels are increased at stages of endocrine differentiation, while a peak of RARa
expression is associated with late differentiation stages (24). Possibly RARa and β together participate in the Pdxl biphasic expression pattern, as reviewed by Soria (39). Thus, suppressing RAR would result exclusively in a late Pdxl expression as observed in treated RARP KO cells (Figure 2).
[000194] Pdxl mis-expression was previously associated with severe β-cell dysfunction and increased cell death (53). Accordingly, RARP KO caused a reduction in β-cell terminal differentiation markers' expression, such as Insl and Iapp in the cell culture system (Figure 3), as well as a decreased number of C-peptide expressing cells in RARP null-mice pancreatic islets (Figure 4). Recent findings by Dalgin et al. (54) also linked RA signaling and endocrine cell fate. Although the authors claimed that β-cell progenitors differentiate as a-cells in RA downstream target mnxl morphants, the data reported here suggest that RARP KO induces a decrease in a- cell differentiation, characterized by reduced expression of glucagon in the cell culture system (Figure 3) and RARP null mice (Figure 4). Thus, the effect observed on islet cells in the absence of RAR could be attributed to the role of RA signaling in early pancreatic differentiation events rather than lineage-specific terminal differentiation.
[000195] Like Pdxl, the bHLH transcription factor Neurogenin3 ( gn3) constitutes another key player in the commitment of endoderm to pancreatic precursors (40, 43, 47). Among the cascade of transcription factors involved in pancreas development, Ngn3 is the earliest to be expressed in the endocrine differentiation pathway (40, 55). While no links between RA signaling and Ngn3 expression was reported in the literature, RARP KO cells displayed decreased levels of this transcription factor during pancreatic differentiation (Figure 3). Thus, the impact of RARP deletion on Ngn3 could be indirect and involving the participation of intermediate factors.
[000196] Pax6 and Isl-1 represent two major transcription factors having a role in endocrine lineage specification after bud formation (45, 56) Considering that Pax6 expression is not affected by RARP KO, and that the Isl-1 peak of expression is only delayed by such a deletion, it appears that absence of RA signaling through RARP is insufficient to completely abrogate endocrine differentiation, but may lead to significant defects in islet cell function.
[000197] The observations reported here indicate that the absence of RARP expression impairs development and maintenance of pancreatic islets in vivo (Figure 4). In mammals, glucose intolerance is characterized by sustained high blood glucose levels (above 140 mg/dL) during at least two hours, while hypoglycemia is decreed when blood concentration goes below 70 mg/dL (50, 57). Blood glucose assessment 1) after 15h fasting and 2) upon dextrose injection led us to suggest that RARP-null mice have a predisposition to fasting hypoglycemia and increased glucose intolerance, two conditions associated with diabetes mellitus (58).
[000198] Close correlations have been made between dietary habits and diabetes, especially for type II (59). Considering the role of RARP in pancreatic endocrine cell differentiation, and that
the ΡνΑΡνβ gene itself is up-regulated by retinoic acid, a sustained vitamin A deficient diet could lead to insufficient islet cell turnover, and eventually to diabetes. ΡνΑΡνβ expression is also known to depend on epigenetic regulation (60, 61). For instance, aberrant hypermethylation of various promoter elements was reported in different pancreatic disorders such as cancer, diabetes, and chronic pancreatitis (62-64). Therefore, epigenetic silencing of ΡνΑΡνβ or other associated effectors could play a role in the onset of certain cases of diabetes.
[000199] The production of insulin secreting endocrine cells from ES cells using RA-based protocols is proposed as a promising tool for diabetic therapy (9). However, ensuring accurate vitamin A consumption and proper RA signaling via RARP represent new avenues to prevent or treat diabetic disorders. In particular, the administration of an RARP agonist would be a specifically targeted method of enhancing this RARP signaling to prevent or treat diabetic disorders. Taken together, these findings shed light on the role of RARP in pancreatic endocrine differentiation, which consequently affects in vivo blood glucose metabolism.
Example 6 RARjJ Agonist Treatment Preparation
[000200] Preparation of AC261066 (a RARp agonist from Tocris) solution. AC261066 was dissolved in dimethyl sulfoxide (DMSO) at the concentration of 1.5 mg/ml, and diluted in the drinking water for mice to the final concentration of 1.5 mg/100 ml.
[000201] Mice, diet, and drug treatment. WT male C57/BL6 male mice were maintained on either a standard laboratory chow-fed diet (CFD) with 13 % kcal fat, (diet# 5053, Lab Diet, Inc, St. Louis, MO) or a high fat, western style diet (HFD) with 60% kcals from fat, (diet #58126, Lab Diet, Inc., St. Louis, MO) for 4 months. One month after the start of the high fat diet treatment, the high fat diet group was further split into 2 groups for 3 months: i) high fat diet and the drinking water containing 1% DMSO; ii) high fat diet and the drinking water containing 1.5 mg/100 ml AC261066, a specific RARP agonist. Then mice were sacrificed by cervical dislocation. Blood and various tissue samples were harvested.
Example 7 Pancreas
[000202] Semi-Quantitate PCR. Total R A was extracted from mouse tissues using TRIzol reagent (Life technologies) and (1 μg ) was used to synthesize cDNA. cDNA synthesis was performed at 42°C for 1 h in a final volume of 20 μΐ using qScript (Quanta, MD). Semiquantitative PCR were performed Taq DNA polymerase (Invitrogen, CA). Three step PCR was run as follows: 94°C for 30 s, 58-64°C for 45 s for primer annealing and 72°C for 1 min for primer extension. The number of cycles for each primer pair for amplification in the linear range was determined experimentally. PCR products were resolved on 2% agarose gels and visualized by staining with ehtidium bromide. Primers for gene expression used were as follows: RARP2, F: 5 '-TGGCATTGTTTGCACGCTGA-3 ' (SEQ ID No. 25), R: 5'- CCCCCCTTTGGCAAAGAATAGA-3 ' (SEQ ID No. 26), CYP26A1, F: 5'-
CTTTATAAGGCCGCCCAGGTTAC-3 ' (SEQ ID No. 27), R: 5'- CCCGATCCGCAATTAAAGATGA-3 ' (SEQ ID No. 28), LRAT, F: 5'- TCTGGCATCTCTCCTACGCTG-3 ' (SEQ ID No. 29), R: 5'- GTTCCAAGTCCTTCAGTCTCTTGC-3 ' (SEQ ID No. 30), INS2, F: 5'- TGTGGGGAGCGTGGCTTCTTCT-3 ' (SEQ ID No. 31), R: 5'- CAGCTCCAGTTGTGCCACTTGT-3 ' (SEQ ID No. 32), HPRT, F:5'-
TGCTCGAGTGTGATGAAGG-3 ' (SEQ ID No. 33), R: 5 ' -TCCCTGTTGACTGGTCATT-3 ' (SEQ ID No. 34).
[000203] Analysis of pancreatic retinoids. The frozen pancreas tissue samples (~ 100 mg) were homogenized in 500 μΐ cold phosphate-buffered saline (PBS). In addition, 100 μΐ serum was diluted in cold PBS to total volume of 500 μΐ. Retinyl acetate was added to each sample before the retinoid extraction for the calculation of extraction efficiency. The retinoids were extracted into 350 μΐ of organic solution (acetonitrile/butanol, 50:50, v/v) in the dark. The high performance liquid chromatography (HPLC) was performed using a Waters Millennium system (Waters). Each sample (100 μΐ of the 350 μΐ) was loaded onto an analytical 5-μιη reverse phase CI 8 column (Vydac, Hesperia, CA) and eluted at a flow rate of 1.5 ml/min. Two mobile phase gradient systems were used. Retinoids were identified by HPLC based on two criteria: an exact match of the retention times of unknown peaks with those of authentic retinoid standards and identical UV light spectra (220-400 nm) of unknowns against spectra from authentic retinoid standards during HPLC by the use of a photodiode array detector. The amounts of retinoids were calculated from the areas under the peaks detected at the wave-length of 325 nm. The levels of retinol and retinyl esters were normalized to the tissue weight.
[000204] 4-hydroxynonenal (4-HNE staining. Paraffin-embedded sections (from two to four mice per group) were deparaffmized and rehydrated, and antigen retrieval was performed using an antigen unmasking solution (Vector Laboratories, H-3300). After quenching endogenous peroxidase with 3% ¾(¾, the tissue sections were blocked with the blocking reagent (from the M.O.M. kit from Vector Laboratories). Then, tissue sections were incubated with a 4-HNE antibody (1 :400; mouse monoclonal antibody; Abeam, ab48506) overnight at 4 °C. The sections were then incubated with secondary antibodies (1 :200, anti-mouse IgG from the M.O.M kit). As a negative control, sections were stained without incubation with primary antibodies. The signals were visualized based on a peroxidase detection mechanism with 3,3-diaminobenzidine (DAB) used as the substrate.
[000205] Retinoid levels in pancreatic tissue. Our HPLC analysis revealed that that pancreata from HF-fed obese mice had dramatically decreased levels retinol (VA, vitamin A) compared to CF (control diet) controls (Fig 5). Retinyl palmitate was undetectable in pancreata tissue from HF-fed mice (Fig 5), showing profound pancreas vitamin A deficiency.
[000206] Serum retinol from mice on a high fat diet vs. control diet compared to the pancreas retinol and retinyl palmitate levels from mice on a high fat vs. control diet. The serum retinol levels are similar or a bit higher in the HF diet mice, but the pancreas retinol levels are much lower in the HF diet mice, showing vitamin A deficiency in the pancreas even in the presence of normal serum vitamin A (Fig 6).
[000207] AC261066 decreases oxidative stress levels in the pancreas from HF-fed mice. High fat diet results in excessive reactive oxygen species (ROS) production that triggers inflammatory responses and subsequent injuries in many tissues. Therefore, we examined the levels of 4- hydroxynonenal (4-HNE), an α,β-unsaturated hydroxyalkenal that is produced by lipid peroxidation in cells during oxidative stress, and is a marker of oxidative stress caused by reactive oxygen species (ROS) in the pancreas. The pancreatic islets from HF-fed mice showed an increase in the 4-HNE levels compared to the chow-fed controls (Fig 7). The pancreatic islet samples from the high fat diet plus AC261066 group exhibited markedly lower 4-HNE staining intensity levels compared to HF-vehicle treated mice (Fig 7).
[000208] AC261066 does diminish pancreatic islet insulin expression. Next we examined the changes to pancreatic expression of endocrine hormones in CF, HF and HF +AC261066 fed mice. Pancreatic islets stained for pro-insulin c-peptide (green) and glucagon (red) revealed that islets from HF and HF + AC261066 fed mice showed a marked increase in c-peptide staining compared to control diet controls (Fig 8). AC261066 slightly decreased c-peptide level in the HF diet mice.
[000209] AC2621066 increased pancreatic mRNA expression of RARjJ in obese and vitamin A deficient mice. Consistent with our HPLC data demonstrating that pancreata tissue from HF- fed, obese mice had significantly decreased VA (vitamin A) levels, and significantly decreased mRNA levels of the VA responsive gene and VA signaling transcription factor, RAR . RAR β was decreased in pancreata of HF-fed obese mice compared to control diet fed mice (Fig 9). mRNA levels of RAR in pancreata HF-AC261066 treated mice were increased compared to HF-vehicle treated mice (Fig 9), and near levels observed in non-obese controls, suggesting that AC261066 can prevent or reverse the loss of VA signaling in VA depleted tissue. Similar findings in vitamin A deficient mice, Fig. 10.
Example 8 Liver
[000210] Hematoxylin and Eosin Staining. At sacrifice, fresh mouse liver samples were fixed in 4% formaldehyde solution for 24 hr and embedded in paraffin blocks. Liver paraffin sections were cut 5 microns thick and mounted on glass slides and stained with hematoxylin and eosin (H and E) using standard protocols.
[000211] Combined oil red O and Immunofluorescence. Staining. Fresh mouse liver samples were embedded in optimal cutting temperature (OCT) medium and immediately frozen to -70
centigrade. Cryosections were then fixed in 4% formaldehyde for 1 hr at room temp. Slides were then rinsed three times in deionized water (dH20) for 30 s, followed by treatment with 0.5% Triton X-100 in PBS for 5 min. Sections were then washed three times with PBS for 5 min. Samples were with incubated 2% bovine serum albumin (BSA) for 30 min at room temperature to block for unspecific antibody binding. Following blocking, sections were washed three times in PBS and incubated with mouse monoclonal antibody against a-SMA (1:500) (Dako, Inc) for 24 h at 4 °C. After 24 h sections were washed three times in PB and incubated with Alexa-Flour- 488 anti-mouse secondary anti-body (1 :500) (Invitrogen, Inc) for 30 min at room temperature. Sections were then washed three times in PBS and incubated with working strength oil-red O solution for 30 minutes at room temperature. Sections were then rinsed for 30 minutes under running tap water and cover- slipped with Vectashield hard mount plus DAPI (Vector Labs, Inc).
[000212] Semi-Quantitate PCR (Liver). Total RNA was extracted from mouse tissues using TRIzol reagent (Life technologies) and (1 μg ) was used to synthesize cDNA. cDNA synthesis was performed at 42°C for 1 h in a final volume of 20 μΐ using qScript (Quanta, MD). Semiquantitative PCR were performed Taq DNA polymerase (Invitrogen, CA). Three step PCR was run as follows: 94°C for 30 s, 58-64°C for 45 s for primer annealing and 72°C for 1 min for primer extension. The number of cycles for each primer pair for amplification in the linear range was determined experimentally. PCR products were resolved on 2% agarose gels and visualized by staining with ehtidium bromide. Primers for gene expression used were as follows: RARP2, F: 5 '-TGGCATTGTTTGCACGCTGA-3 ' (SEQ ID No. 25), R: 5'- CCCCCCTTTGGCAAAGAATAGA-3 ' (SEQ ID No. 26), CYP26A1, F: 5'- CTTTATAAGGCCGCCCAGGTTAC-3 ' (SEQ ID No. 27), R: 5'- CCCGATCCGCAATTAAAGATGA-3 ' (SEQ ID No. 28), LRAT, F: 5'- TCTGGCATCTCTCCTACGCTG-3 ' (SEQ ID No. 29), R: 5'- GTTCCAAGTCCTTCAGTCTCTTGC-3 ' (SEQ ID No. 30), INS2, F: 5'- TGTGGGGAGCGTGGCTTCTTCT-3 ' (SEQ ID No. 31), R: 5'- CAGCTCCAGTTGTGCCACTTGT-3 ' (SEQ ID No. 32), TNF , F: 5'- CCTGTAGCCCACGTCGTAG-3 ' (SEQ ID No. 35), R: 5'- GGGAGTAGACAAGGTACAACCC-3 ' (SEQ ID No. 36), MCP1, F: 5'- TTAAAAACCTGGATCGGAACCAA-3 ' (SEQ ID No. 37), R: 5'- GCATTAGCTTCAGATTTACGGGT-3 ' (SEQ ID No. 38), HPRT, F:5'- TGCTCGAGTGTGATGAAGG-3 ' (SEQ ID No. 33), R: 5 ' -TCCCTGTTGACTGGTCATT-3 ' (SEQ ID No. 34).
[000213] Serum triglyceride level measurement. The analysis of serum triglyceride levels was carried out using a bichromatic assay at the Laboratory of Comparative Pathology of the
Memorial Sloan-Kettering Cancer Center. Chow-fed diet (CFD) n=2; high fat diet (HFD) n=3; high fat diet+AC261066 (HFDAC) n=5.
[000214] Analysis of serum and liver retinoids. The frozen liver tissue samples (~ 100 mg) were homogenized in 500 μΐ cold phosphate-buffered saline (PBS). In addition, 100 μΐ serum was diluted in cold PBS to total volume of 500 μΐ. Retinyl acetate was added to each sample before the retinoid extraction for the calculation of extraction efficiency. The retinoids were extracted into 350 μΐ of organic solution (acetonitrile/butanol, 50:50, v/v) in the dark. The high performance liquid chromatography (HPLC) was performed using a Waters Millennium system (Waters). Each sample (100 μΐ of the 350 μΐ) was loaded onto an analytical 5-μιη reverse phase CI 8 column (Vydac, Hesperia, CA) and eluted at a flow rate of 1.5 ml/min. Two mobile phase gradient systems were used. Retinoids were identified by HPLC based on two criteria: an exact match of the retention times of unknown peaks with those of authentic retinoid standards and identical UV light spectra (220-400 nm) of unknowns against spectra from authentic retinoid standards during HPLC by the use of a photodiode array detector. The amounts of retinoids were calculated from the areas under the peaks detected at the wave-length of 325 nm. The levels of retinol and retinyl esters were normalized to the tissue weight.
[000215] 4-hydroxynonenal (4-HNE) staining. Paraffin-embedded sections (from two to four mice per group) were deparaffmized and rehydrated, and antigen retrieval was performed using an antigen unmasking solution (Vector Laboratories, H-3300). After quenching endogenous peroxidase with 3% H202, the tissue sections were blocked with the blocking reagent (from the M.O.M. kit from Vector Laboratories). Then, tissue sections were incubated with a 4-HNE antibody (1 :400; mouse monoclonal antibody; Abeam, ab48506) overnight at 4 °C. The sections were then incubated with secondary antibodies (1 :200, anti-mouse IgG from the M.O.M kit). As a negative control, sections were stained without incubation with primary antibodies. The signals were visualized based on a peroxidase detection mechanism with 3,3-diaminobenzidine (DAB) used as the substrate.
[000216] Analysis of serum and liver retinoids. The frozen liver tissue samples (~ 100 mg) were homogenized in 500 μΐ cold phosphate-buffered saline (PBS). In addition, 100 μΐ serum was diluted in cold PBS to total volume of 500 μΐ. Retinyl acetate was added to each sample before the retinoid extraction for the calculation of extraction efficiency. The retinoids were extracted into 350 μΐ of organic solution (acetonitrile/butanol, 50:50, v/v) in the dark. The high performance liquid chromatography (HPLC) was performed using a Waters Millenium system (Waters). Each sample (100 μΐ of the 350 μΐ) was loaded onto an analytical 5-μιη reverse phase CI 8 column (Vydac, Hesperia, CA) and eluted at a flow rate of 1.5 ml/min. Two mobile phase gradient systems were used. Retinoids were identified by HPLC based on two criteria: an exact match of the retention times of unknown peaks with those of authentic retinoid standards and
identical UV light spectra (220-400 nm) of unknowns against spectra from authentic retinoid standards during HPLC by the use of a photodiode array detector. The amounts of retinoids were calculated from the areas under the peaks detected at the wave-length of 325 nm. The levels of retinol and retinyl esters were normalized to the tissue weight.
[000217] AC261066 diminished hepatic steatosis. H and E staining of liver sections from treatment mice revealed that 4 months of a HF western style diet lead to increased hepatocyte lipid accumulation in HF-fed mice compared to CFD-fed mice (Fig 11). HF-fed mice treated with AC261066 showed marked decreased hepatocyte lipid infiltration compared to HF -vehicle treated mice (Fig 11). HF-fed mice treated with a RAR γ ligand (CD1530) showed no decrease in hepatic lipid accumulation (Fig 1 1).
[000218] AC261066 diminishes hepatic gene expression of alpha-SMA (alpha-smooth muscle actin) and SREBPlc. Consistent with our immunofluorescence microscopy showing that a- SMA protein is decreased in HF-AC261011 fed mice compared to HF -vehicle controls, hepatic mRNA levels of alpha-SMA were also decreased in livers of HF-AC26101 1 fed mice, but not in the livers of HF-CD1530 treated mice (Fig 12). We also measured mRNA expression of SREBPl-c, which codes for a transcription factor responsible for de novo synthesis of triglyceride and is often over-expressed in livers of animals with experimentally induced NAFLD. Our analysis revealed that mRNA levels of SREBPl-c are markedly higher in livers of HF-fed and HF-fed CD1530 treated mice, but not in livers of HF-AC26101 1 treated mice (Fig 12).
[000219] AC261066 diminishes hepatic stellate cell (HSC) activation. Liver sections co-stained with the neutral lipid stain oil-red-o were in agreement with the H and E staining, demonstrating that HF-fed obese mice had ectopic accumulation of hepatic lipids (red) compared to CF controls (Fig 13). Livers of HF-AC261066-fed mice had marked diminished hepatic lipid accumulation compared to HF vehicle-fed mice (Fig 13). This effect was not observed in the livers of HF-fed mice treated with the CD1530 (RARy agonist).
[000220] Activated HSCs contribute to normal liver tissue repair processes, but unresolved HSC activation can lead to fibrotic lesion formation and the progression of steatosis to advanced NAFLD, such as non-alcoholic steatohepatitis (NASH). To examine whether HF-fed obese mice exhibited evidence of increased activation of HSCs we stained liver sections with an a-SMA antibody. This analysis revealed the livers of HF-fed mice had increased a-SMA positive (green) staining compared to lean, CF controls. a-SMA positive areas tended to cluster in areas with hepatocyte lipid infiltration (Fig 13). Compared to HF-fed mice, livers of HF-fed-AC261066 treated mice had decreased intensity and regions of a-SMA positive staining (Fig 13). Moreover, clustering a-SMA in lipid positive (red) regions was not observed in liver of HF-AC261066 treated mice. Livers of HF-fed CD 1530 treated mice had no evidence decreased lipid
accumulation or a-SMA expression intensity or patterns compared to HF fed-vehicle treated mice.
[000221] AC261066 diminishes hepatic gene expression of pro-inflammatory mediators.
NAFLD is typically associated with increased hepatic expression of pro-inflammatory cytokines and mediators such as the monocyte chemokine MCP-1 and the cytokine TNF-a. We examined expression of these genes in livers of CF and HF-fed mice. Our analysis revealed that mRNA levels of both MCP-1 and TNF-a were markedly elevated in livers of HF-fed mice HF-fed CD1530 treated mice, but not in livers of HF-fed AC261066 treated mice (Fig 14).
[000222] AC261066 does not elevate serum triglyceride levels. We examined the triglyceride levels in mouse serum samples because elevated triglycerides are a risk factor for cardiovascular disease. As shown in Fig 15, HF or HF + AC261066 feeding does not affect serum triglyceride levels compared CF controls. This suggests that AC261066 does not increase risk for cardiovascular disease and suggests that the liver lipid lowering effect of AC261066 does not correlate with increased hepatic lipid export.
[000223] AC261066 partially reverses depletion of VA in livers of HF-fed Obese Mice. The liver stores approximately 80-90% of total body VA, therefore we conducted HPLC to determine the tissue levels of the major storage form of VA, retinyl-palmitate and of all-trans retinol in lean CF, HF and HF + AC261066 fed mice. Our analysis revealed that levels of retinyl-palmitate and retinol were decreased by 97% and 92% in livers in HF-fed, obese mice compared to lean, CF controls(Fig 16). Serum levels of the major circulating form of VA, all-trans retinol were not different between CF, HF and HF + AC261066 fed mice, suggesting that HF-driven obesity leads to tissue VA depletion which is not reflected by serum VA levels.
[000224] Livers of mice fed HF + AC261066 and CD1530 also had significantly lowered retinyl palmitate and retinol compared to controls, however compared to HF-vehicle treated mice, we observed 55% higher levels of retinyl palmitate in the livers from HF-AC261066 fed mice, while retinyl palmitate levels in the liver of HF + CD1530 treated mice were almost 48% lower than livers from HF-vehicle treated mice (Fig 16). This suggests that longer administration of AC261066 to HF-fed obese mice may have significantly reversed HF-obesity driven liver VA depletion.
[000225] Oxidative stress level, as assessed by 4-hydroxynoneal (4-HNE), is lower in the liver from the high fat diet plus AC261066 group than that in the high fat diet group. High fat diet results in excessive reactive oxygen species (ROS) production that triggers inflammatory responses and subsequent injuries in many tissues. Therefore, we examined the levels of 4- hydroxynonenal (4-HNE), an α,β-unsaturated hydroxyalkenal that is produced by lipid peroxidation in cells during oxidative stress, and is a marker of oxidative stress caused by reactive oxygen species (ROS) in the liver.. The liver from the high fat diet group showed a large
increase in the 4-HNE levels compared to the control fat diet group, and the liver samples from the high fat diet plus AC261066 group exhibited lower 4-HNE levels than those from the high fat diet group (Fig. 17).
Example 9 Kidney
[000226] Hematoxylin and Eosin Staining. At sacrifice, fresh mouse liver samples were fixed in 4% formaldehyde solution for 24 hr and embedded in paraffin blocks. Kidney paraffin sections were cut 5 microns thick and mounted on glass slides and stained with hematoxylin and eosin (H and E) using standard protocols.
[000227] Combined oil red O and Immunofluorescence staining. Fresh mouse kidney samples were embedded in optimal cutting temperature (OCT) medium and immediately frozen to -70 centigrade. Cryosections were then fixed in 4% formaldehyde for 1 hr at room temp. Slides were then rinsed three times in deionized water (dH20) for 30 s, followed by treatment with 0.5% Triton X-100 in PBS for 5 min. Sections were then washed three times with PBS for 5 min. Samples were with incubated 2% bovine serum albumin (BSA) for 30 min at room temperature to block for unspecific antibody binding. Following blocking, sections were washed three times in PBS and incubated with mouse monoclonal antibody against a-SMA (1:500) (Dako, Inc) for 24 h at 4 °C. After 24 h sections were washed three times in PB and incubated with Alexa-Flour- 488 anti-mouse secondary anti-body (1 :500) (Invitrogen, Inc) for 30 min at room temperature. Sections were then washed three times in PBS and incubated with working strength oil-red O solution for 30 minutes at room temperature. Sections were then rinsed for 30 minutes under running tap water and cover- slipped with Vectashield hard mount plus DAPI (Vector Labs, Inc).
[000228] Semi-Quantitative PCR. Total RNA was extracted from mouse tissues using TRIzol reagent (Life technologies) and (1 μg ) was used to synthesize cDNA. cDNA synthesis was performed at 42°C for 1 h in a final volume of 20 μΐ using qScript (Quanta, MD). Semiquantitative PCR were performed Taq DNA polymerase (Invitrogen, CA). Three step PCR was run as follows: 94°C for 30 s, 58-64°C for 45 s for primer annealing and 72°C for 1 min for primer extension. The number of cycles for each primer pair for amplification in the linear range was determined experimentally. PCR products were resolved on 2% agarose gels and visualized by staining with ehtidium bromide. Primers for gene expression used were as follows: RARP2, F: 5 '-TGGCATTGTTTGCACGCTGA-3 ' (SEQ ID No. 25), R: 5'- CCCCCCTTTGGCAAAGAATAGA-3 ' (SEQ ID No. 26), CYP26A1, F: 5'- CTTTATAAGGCCGCCCAGGTTAC-3 ' (SEQ ID No. 27), R: 5'- CCCGATCCGCAATTAAAGATGA-3 ' (SEQ ID No. 28), TNF , F: 5'- CCTGTAGCCCACGTCGTAG-3 ' (SEQ ID No. 35), R: 5'- GGGAGTAGACAAGGTACAACCC-3 ' (SEQ ID No. 36), HPRT, F: 5'-
TGCTCGAGTGTGATGAAGG-3 ' (SEQ ID No. 33), R: 5 ' -TCCCTGTTGACTGGTCATT-3 ' (SEQ ID No. 34).
[000229] Analysis of kidney retinoids. The frozen kidney tissue samples (~100 mg) were homogenized in 500 μΐ cold phosphate-buffered saline (PBS). In addition, 100 μΐ serum was diluted in cold PBS to total volume of 500 μΐ. Retinyl acetate was added to each sample before the retinoid extraction for the calculation of extraction efficiency. The retinoids were extracted into 350 μΐ of organic solution (acetonitrile/butanol, 50:50, v/v) in the dark. The high performance liquid chromatography (HPLC) was performed using a Waters Millennium system (Waters). Each sample (100 μΐ of the 350 μΐ) was loaded onto an analytical 5-μιη reverse phase CI 8 column (Vydac, Hesperia, CA) and eluted at a flow rate of 1.5 ml/min. Two mobile phase gradient systems were used. Retinoids were identified by HPLC based on two criteria: an exact match of the retention times of unknown peaks with those of authentic retinoid standards and identical UV light spectra (220-400 nm) of unknowns against spectra from authentic retinoid standards during HPLC by the use of a photodiode array detector. The amounts of retinoids were calculated from the areas under the peaks detected at the wave-length of 325 nm. The levels of retinol and retinyl esters were normalized to the tissue weight.
[000230] 4-hydroxynonenal (4-HNE staining. Paraffin-embedded sections (from two to four mice per group) were deparaffmized and rehydrated, and antigen retrieval was performed using an antigen unmasking solution (Vector Laboratories, H-3300). After quenching endogenous peroxidase with 3% ¾(¾, the tissue sections were blocked with the blocking reagent (from the M.O.M. kit from Vector Laboratories). Then, tissue sections were incubated with a 4-HNE antibody (1 :400; mouse monoclonal antibody; Abeam, ab48506) overnight at 4 °C. The sections were then incubated with secondary antibodies (1 :200, anti-mouse IgG from the M.O.M kit). As a negative control, sections were stained without incubation with primary antibodies. The signals were visualized based on a peroxidase detection mechanism with 3,3-diaminobenzidine (DAB) used as the substrate.
[000231] AC261066 diminished renal lipid accumulation. H and E staining of kidney sections from treatment mice revealed that 4 months of a HF western style diet lead to increased renal lipid accumulation in HF-fed mice compared to CFD-fed mice (Fig 18). HF-fed mice treated with AC261066 showed markedly decreased renal lipid infiltration compared to HF -vehicle treated mice (Fig 18). HF-fed mice treated with a RAR γ ligand (CD1530) showed no decrease in renal lipid accumulation (Fig 18).
[000232] AC261066 diminishes renal expression of alpha-SMA. Kidney sections co-stained with the neutral lipid stain oil-red-o were in agreement with the H and E staining, demonstrating that HF-fed obese mice had ectopic accumulation of renal lipids (red) compared to CF controls (Fig 18). Kidneys of HF-AC261066-fed mice had marked diminished hepatic lipid accumulation
compared to HF vehicle-fed mice (Fig 19). Alpha-SMA is required for normal kidney tissue repair processes, but unchecked alpha-SMA secretion can lead to fibrotic lesion formation and the progression of advanced renal disease. As expected kidney sections stained with the neutral lipid stain oil-red-o (red) showed marked increase in renal lipid droplets in kidneys of HF-fed mice compared to control fed mice. In agreement with our H and E histological analysis, kidney sections from HF + AC261066 treated mice had comparably less oil red o positive areas. a-SMA (green) staining also revealed that kidneys of HF-fed mice had increased a-SMA positive areas compared to control fed mice (Fig 19). This increase in a-SMA positive areas was not observed in kidneys of HF + AC261066 treated mice.
[000233] Retinoid levels in kidneys. Our HPLC analysis of kidney tissue demonstrated that HF- fed obese mice had significantly decreased levels of kidney retinyl palmitate and retinol compared to chow fed controls (Fig 20).
[000234] AC261066 diminishes kidney gene expression of pro-inflammatory mediators.
Fibrosis is associated increased renal expression of pro-inflammatory cytokines and mediators. We examined whether kidneys of HF-fed mice had evidence of inflammation marked by increased expression of inflammatory cytokines such as TNF-a. Our analysis revealed that mRNA levels of TNF-a were markedly elevated in livers of HF-fed mice, but not in livers of HF-fed AC261066 treated mice (Fig 21).
[000235] AC261066 increased kidney gene expression of RARP2. Consistent with the HPLC data demonstrating that VA levels are diminished in kidney of HF-fed mice, our kidney gene expression analysis revealed that RARP2 mRNA is markedly decreased in the kidney of HF-fed mice (Fig 21). Kidney's from HF-AC261066 did not have decreased RAR 2 mRNA levels (Fig 21).
[000236] Oxidative stress level, as assessed by 4-hydroxynoneal (4-HNE), is lower in the kidneys from the high fat diet plus AC261066 group than that in the high fat diet group.
High fat diet results in excessive reactive oxygen species (ROS) production that triggers inflammatory responses and subsequent injuries in many tissues. Therefore, we examined the levels of 4-hydroxynonenal (4-HNE), an α,β-unsaturated hydroxyalkenal that is produced by lipid peroxidation in cells during oxidative stress, and is a marker of oxidative stress caused by reactive oxygen species (ROS) in the kidneys The kidneys from the high fat diet group showed a large increase in the 4-HNE levels compared to the control fat diet group, and the kidneys from the high fat diet plus AC261066 group exhibited lower 4-HNE levels than those from the high fat diet group (Fig.22).
Example 10 TESTES
[000237] Semi-Quantitative PCR. Total RNA was extracted from mouse tissues using TRIzol reagent (Life technologies) and (1 μg ) was used to synthesize cDNA. cDNA synthesis was
performed at 42°C for 1 h in a final volume of 20 μΐ using qScript (Quanta, MD). Semiquantitative PCR were performed Taq DNA polymerase (Invitrogen, CA). Three step PCR was run as follows: 94°C for 30 s, 58-64°C for 45 s for primer annealing and 72°C for 1 min for primer extension. The number of cycles for each primer pair for amplification in the linear range was determined experimentally. PCR products were resolved on 2% agarose gels and visualized by staining with ehtidium bromide. Primers for gene expression used were as follows: RARP2, F: 5 '-TGGCATTGTTTGCACGCTGA-3 ' (SEQ ID No. 25), R: 5'- CCCCCCTTTGGCAAAGAATAGA-3 ' (SEQ ID No. 26), CYP26A1, F: 5'- CTTTATAAGGCCGCCCAGGTTAC-3 ' (SEQ ID No. 27), R: 5'- CCCGATCCGCAATTAAAGATGA-3 ' (SEQ ID No. 28), HPRT, F: 5'- TGCTCGAGTGTGATGAAGG-3 ' (SEQ ID No. 33), R: 5 ' -TCCCTGTTGACTGGTCATT-3 ' (SEQ ID No. 34).
[000238] Analysis of testes retinoids. The frozen kidney tissue samples (~100 mg) were homogenized in 500 μΐ cold phosphate-buffered saline (PBS). In addition, 100 μΐ serum was diluted in cold PBS to total volume of 500 μΐ. Retinyl acetate was added to each sample before the retinoid extraction for the calculation of extraction efficiency. The retinoids were extracted into 350 μΐ of organic solution (acetonitrile/butanol, 50:50, v/v) in the dark. The high performance liquid chromatography (HPLC) was performed using a Waters Millennium system (Waters). Each sample (100 μΐ of the 350 μΐ) was loaded onto an analytical 5-μιη reverse phase C18 column (Vydac, Hesperia, CA) and eluted at a flow rate of 1.5 ml/min. Two mobile phase gradient systems were used. Retinoids were identified by HPLC based on two criteria: an exact match of the retention times of unknown peaks with those of authentic retinoid standards and identical UV light spectra (220-400 nm) of unknowns against spectra from authentic retinoid standards during HPLC by the use of a photodiode array detector. The amounts of retinoids were calculated from the areas under the peaks detected at the wave-length of 325 nm. The levels of retinol and retinyl esters were normalized to the tissue weight.
[000239] Retinoid levels in testes. Our HPLC analysis of testes demonstrated that HF-fed obese mice had significantly decreased levels of retinyl palmitate (storage form of VA) and decreased retinol compared to chow fed controls (Fig 23).
[000240] Testes of HF-fed Mice have decreased expression of VA relevant genes expression.
Consistent with the HPLC data demonstrating that VA levels are diminished in kidney of HF-fed mice, our testes gene expression analysis revealed that RARP2 and CYP26A1, and RAR gamma2 mRNAs are markedly decreased in the testes of HF-fed mice (Fig 24).
[000241] RARp agonist AC55649 is prepared in the same way and is used to treat mice as described in Examples 6-10.
242] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices and materials are herein described. All publications mentioned herein are hereby incorporated by reference in their entirety for the purpose of describing and disclosing the materials and methodologies that are reported in the publication which might be used in connection with the invention.
REFERENCES
1. Guariguata L, Whiting D, Weil C, Unwin N. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. Diabetes research and clinical practice2011 Dec;94(3):322-32.
2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 201 1 and 2030. Diabetes research and clinical practice. [Research Support, Non-U.S. Gov't]. 201 1 Dec;94(3):31 1-21.
3. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2009 Dec;32(12):2225-9.
4. Oliver-Krasinski JM, Staffers DA. On the origin of the beta cell. Genes & development. [Research Support, N.I.H., Extramural Review]. 2008 Aug 1;22(15): 1998-2021.
5. Waldron-Lynch F, Herold KC. Immunomodulatory therapy to preserve pancreatic beta- cell function in type 1 diabetes. Nature reviews Drug discovery. [Review]. 2011 Jun; 10(6):439- 52.
6. Waldron-Lynch F, von Herrath M, Herold KC. Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass. Novartis Foundation symposium2008;292: 146-55; discussion 55-8, 202-3.
7. Charbonnel B, Penfornis A, Varroud-Vial M, Kusnik-Joinville O, Detournay B. Insulin therapy for diabetes mellitus: Treatment regimens and associated costs. Diabetes & metabolism201 1 Dec 13.
8. Soria B, Andreu E, Berna G, Fuentes E, Gil A, Leon-Quinto T, Martin F, Montanya E, Nadal A, Reig JA, Ripoll C, Roche E, Sanchez-Andres JV, Segura J. Engineering pancreatic islets. Pflugers Archiv - European Journal of Physiology2000;440(l): l-18.
9. Zaret KS, Grompe M. Generation and regeneration of cells of the liver and pancreas. Science. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 2008 Dec 5;322(5907): 1490-4.
10. Weir GC, Cavelti-Weder C, Bonner- Weir S. Stem cell approaches for diabetes: towards beta cell replacement. Genome medicine2011;3(9):61.
11. Sui J, Mehta M, Shi B, Morahan G, Jiang FX. Directed Differentiation of Embryonic Stem Cells Allows Exploration of Novel Transcription Factor Genes for Pancreas Development. Stem cell reviews2012 Jan 26; 1(1): 1-10.
12. Ben-Yehudah A, White C, Navara CS, Castro CA, Ize-Ludlow D, Shaffer B, Sukhwani M, Mathews CE, Chaillet JR, Witchel SF. Evaluating protocols for embryonic stem cell differentiation into insulin-secreting beta-cells using insulin II-GFP as a specific and noninvasive reporter. Cloning Stem Cells2009 Jun;l l(2):245-57.
13. Blyszczuk P, Czyz J, Kania G, Wagner M, Roll U, St-Onge L, Wobus AM. Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin- producing cells. Proc Natl Acad Sci U S A. [Research Support, Non-U. S. Gov't]. 2003 Feb 4;100(3):998-1003.
14. Borowiak M, Maehr R, Chen S, Chen AE, Tang W, Fox JL, Schreiber SL, Melton DA. Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell2009 Apr 3;4(4):348-58.
15. D mour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, Moorman MA, Kroon E, Carpenter MK, Baetge EE. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. [Research Support, Non-U. S. Gov't]. 2006 Nov;24(l l): 1392-401.
16. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H, Richardson M, Smart NG, Cunningham J, Agulnick AD, D'Amour KA, Carpenter MK, Baetge EE. Pancreatic endoderm derived from human embryonic stem cells generates glucose- responsive insulin-secreting cells in vivo. Nat Biotechnol2008 Apr;26(4):443-52.
17. Micallef SJ, Janes ME, Knezevic K, Davis RP, Elefanty AG, Stanley EG. Retinoic acid induces Pdxl -positive endoderm in differentiating mouse embryonic stem cells. Diabetes2005 Feb;54(2):301-5.
18. Laursen KB, Wong PM, Gudas LJ. Epigenetic regulation by RARalpha maintains ligand- independent transcriptional activity. Nucleic acids research2012 Jan;40(l): 102-15.
19. Jaramillo M, Banerjee I. Endothelial cell co-culture mediates maturation of human embryonic stem cell to pancreatic insulin producing cells in a directed differentiation approach. J Vis Exp2012(61).
20. Chen Y, Pan FC, Brandes N, Afelik S, Solter M, Pieler T. Retinoic acid signaling is essential for pancreas development and promotes endocrine at the expense of exocrine cell differentiation in Xenopus. Developmental biology. [Comparative Study Research Support, Non- U.S. Gov't]. 2004 Jul 1;271(1): 144-60.
21. Ostrom M, Loffler KA, Edfalk S, Selander L, Dahl U, Ricordi C, Jeon J, Correa-Medina M, Diez J, Edlund H. Retinoic acid promotes the generation of pancreatic endocrine progenitor cells and their further differentiation into beta-cells. PLoS One. [Research Support, Non-U.S. Gov't]. 2008;3(7):e2841.
22. Matthews KA, Rhoten WB, Driscoll HK, Chertow BS. Vitamin A deficiency impairs fetal islet development and causes subsequent glucose intolerance in adult rats. The Journal of nutrition. [Research Support, U.S. Gov't, P.H.S.]. 2004 Aug;134(8): 1958-63.
23. Chertow BS, Blaner WS, Baranetsky NG, Sivitz WI, Cordle MB, Thompson D, Meda P. Effects of vitamin A deficiency and repletion on rat insulin secretion in vivo and in vitro from isolated islets. J Clin Invest. [In Vitro Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 1987 Jan;79(l): 163-9.
24. Dodge R, Loomans C, Sharma A, Bonner- Weir S. Developmental pathways during in vitro progression of human islet neogenesis. Differentiation. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2009 Feb;77(2): 135-47.
25. Dolle P, Ruberte E, Leroy P, Morriss-Kay G, Chambon P. Retinoic acid receptors and cellular retinoid binding proteins. I. A systematic study of their differential pattern of transcription during mouse organogenesis. Development. [Research Support, Non-U.S. Gov't]. 1990 Dec;110(4): l 133-51.
26. Ghyselinck NB, Dupe V, Dierich A, Messaddeq N, Gamier JM, Rochette-Egly C, Chambon P, Mark M. Role of the retinoic acid receptor beta (RAR ) during mouse development. The International journal of developmental biology. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 1997 Jun;41(3):425-47.
27. Martinez-Ceballos E, Gudas LJ. Hoxal is required for the retinoic acid- induced differentiation of embryonic stem cells into neurons. Journal of neuroscience research. [Research Support, N.I.H., Extramural]. 2008 Oct;86(13):2809-19.
28. Martinez-Ceballos E, Chambon P, Gudas LJ. Differences in gene expression between wild type and Hoxal knockout embryonic stem cells after retinoic acid treatment or leukemia inhibitory factor (LIF) removal. The Journal of biological chemistry. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.]. 2005 Apr 22;280(16):16484-98.
29. Benoit YD, Lussier C, Ducharme PA, Sivret S, Schnapp LM, Basora N, Beaulieu JF. Integrin alpha8betal regulates adhesion, migration and proliferation of human intestinal crypt cells via a predominant RhoA/ROCK-dependent mechanism. Biology of the cell / under the auspices of the European Cell Biology Organization. [Research Support, Non-U.S. Gov't]. 2009 Dec;101(12):695-708.
30. Benoit YD, Pare F, Francoeur C, Jean D, Tremblay E, Boudreau F, Escaffit F, Beaulieu JF. Cooperation between HNF-1 alpha, Cdx2, and GATA-4 in initiating an enterocytic
differentiation program in a normal human intestinal epithelial progenitor cell line. American journal of physiology Gastrointestinal and liver physiology. [Research Support, Non-U.S. Gov't]. 2010 Apr;298(4):G504-17.
31. Auclair BA, Benoit YD, Rivard N, Mishina Y, Perreault N. Bone morphogenetic protein signaling is essential for terminal differentiation of the intestinal secretory cell lineage. Gastroenterology2007 Sep;133(3):887-96.
32. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab2011 Oct 5;14(4):528-36.
33. Spokoini R, Kfir-Erenfeld S, Yefenof E, Sionov RV. Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis. Mol Endocrinol2010 Jun;24(6): l 136- 50.
34. Yamaguchi TP, Takada S, Yoshikawa Y, Wu N, McMahon AP. T (Brachyury) is a direct target of Wnt3a during paraxial mesoderm specification. Genes & developmentl999 Dec 15;13(24):3185-90.
35. Otonkoski T, Beattie GM, Mally MI, Ricordi C, Hayek A. Nicotinamide is a potent inducer of endocrine differentiation in cultured human fetal pancreatic cells. J Clin Invest 1993 Sep;92(3): 1459-66.
36. Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R, McKay R. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science. [Research Support, Non-U.S. Gov't]. 2001 May 18;292(5520): 1389-94.
37. Marchand M, Schroeder IS, Markossian S, Skoudy A, Negre D, Cosset FL, Real P, Kaiser C, Wobus AM, Savatier P. Mouse ES cells over-expressing the transcription factor NeuroD 1 show increased differentiation towards endocrine lineages and insulin-expressing cells. The International journal of developmental biology. [Research Support, Non-U.S. Gov't]. 2009;53(4):569-78.
38. Langton S, Gudas LJ. CYP26A1 knockout embryonic stem cells exhibit reduced differentiation and growth arrest in response to retinoic acid. Developmental biology. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. 2008 Mar 15;315(2):331-54.
39. Soria B. In-vitro differentiation of pancreatic beta-cells. Differentiation2001 Oct;68(4- 5):205-19.
40. Van Hoof D, D'Amour KA, German MS. Derivation of insulin-producing cells from human embryonic stem cells. Stem cell research. [Research Support, Non-U.S. Gov't
Review]. 2009 Sep-Nov;3(2-3):73-87.
41. Bernardo AS, Hay CW, Docherty K. Pancreatic transcription factors and their role in the birth, life and survival of the pancreatic beta cell. Mol Cell Endocrinol2008 Nov 6;294(l-2): 1-9.
42. Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, Gudas LJ, Mongan NP. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem cells and development2009 Sep;18(7): 1093-108.
43. Rukstalis JM, Habener JF. Neurogenin3: a master regulator of pancreatic islet differentiation and regeneration. Islets2009 Nov-Dec;l(3): 177-84.
44. Gosmain Y, Katz LS, Masson MH, Cheyssac C, Poisson C, Philippe J. Pax6 is crucial for beta-cell function, insulin biosynthesis, and glucose-induced insulin secretion. Mol Endocrinol. [Research Support, Non-U.S. Gov't]. 2012 Apr;26(4):696-709.
45. Ahlgren U, Pfaff SL, Jessell TM, Edlund T, Edlund H. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature. [Research Support, Non-U.S. Gov't]. 1997 Jan 16;385(6613):257-60.
46. Naujok O, Francini F, Picton S, Bailey CJ, Lenzen S, Jorns A. Changes in gene expression and morphology of mouse embryonic stem cells on differentiation into insulin- producing cells in vitro and in vivo. Diabetes Metab Res Rev2009 Jul;25(5):464-76.
47. Gasa R, Mrejen C, Leachman N, Otten M, Barnes M, Wang J, Chakrabarti S, Mirmira R, German M. Proendocrine genes coordinate the pancreatic islet differentiation program in vitro. Proc Natl Acad Sci U S A2004 Sep 7;101(36): 13245-50.
48. Steiner DF, Cunningham D, Spigelman L, Aten B. Insulin biosynthesis: evidence for a precursor. Sciencel967 Aug 11;157(3789):697-700.
49. Daly ME, Vale C, Walker M, Littlefield A, Alberti KG, Mathers JC. Acute effects on insulin sensitivity and diurnal metabolic profiles of a high-sucrose compared with a high-starch diet. Am J Clin Nutrl998 Jun;67(6): 1186-96.
50. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism2009 Mar;94(3):709- 28.
51. Cai J, Yu C, Liu Y, Chen S, Guo Y, Yong J, Lu W, Ding M, Deng H. Generation of homogeneous PDX1(+) pancreatic progenitors from human ES cell-derived endoderm cells. J Mol Cell Biol. [Research Support, Non-U.S. Gov't]. 2010 Feb;2(l):50-60.
52. Jonsson J, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. Naturel994 Oct 13;371(6498):606-9.
53. Fujimoto K, Polonsky KS. Pdxl and other factors that regulate pancreatic beta-cell survival. Diabetes, obesity & metabolism2009 Nov; 11 Suppl 4:30-7.
54. Dalgin G, Ward AB, Hao le T, Beattie CE, Nechiporuk A, Prince VE. Zebrafish mnxl controls cell fate choice in the developing endocrine pancreas. Development2011 Nov; 138(21):4597-608.
55. Vetere A, Marsich E, Di Piazza M, Koncan R, Micali F, Paoletti S. Neurogenin3 triggers beta-cell differentiation of retinoic acid-derived endoderm cells. The Biochemical journal2003 May l ;371(Pt 3):831-41.
56. Dohrmann C, Gruss P, Lemaire L. Pax genes and the differentiation of hormone producing endocrine cells in the pancreas. Mech Dev2000 Mar 15;92(l):47-54.
57. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care2005 Jan;28 Suppl l :S37-42.
58. Del Prato S, Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res2004 Nov-Dec;36(l 1-12):775-81.
59. Riserus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. Prog Lipid Res2009 Jan;48(l):44-51.
60. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, Toma S, Nicolo G, Sacchi N. Endogenous reactivation of the RAR 2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer research2002 May 1 ;62(9):2455-61.
61. Youssef EM, Estecio MR, Issa JP. Methylation and regulation of expression of different retinoic acid receptor beta isoforms in human colon cancer. Cancer Biol Ther2004 Jan;3(l):82-6.
62. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg2003 Sep;238(3):423-31 ; discussion 31-2.
63. Sato N, Fukushima N, Hruban RH, Goggins M. CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol2008 Mar;21(3):238-44.
64. Volkmar M, Dedeurwaerder S, Cunha DA, Ndlovu M , Defrance M, Deplus R, Calonne E, Volkmar U, Igoillo-Esteve M, Naamane N, Del Guerra S, Masini M, Bugliani M, Marchetti P, Cnop M, Eizirik DL, Fuks F. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. EMBO J2012 Mar 21;31(6): 1405-26.
65. Lund, B. W.; Piu, F.; Gauthier, N. K.; Eeg, A.; Currier, E.; Sherbukhin,V.; Brann, M. R.; Hacksell, U.; Olsson, R. Discovery of a Potent,Orally Available, and Isoform-Selective Retinoic Acid beta2 Receptor Agonist. J. Med. Chem. 2005, 48, 7517-7519
66. Vivat-Hannah V et al, Synergistic Cytotoxicity Exhibited by Combination Treatment of Selective Retinoid Ligands with Taxol (Paclitaxel). Cancer Res. 2001, 61, 8703-871 1.
67. Millikan LE, Adapalene: an update on newer comparative studies between the various retinoids. Int. J.Dermatol..2000, 39, 784-88.
68. Chen JY et al (1995) RAR-specific agonist/antagonists which dissociate transactivation and API transrepression inhibit anchorage-independent cell proliferation. EMBO J. 1995, 14, 1 187- 97.
69. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM.Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013; 1 :38-45.
70. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 11 :686-90.
71. Baffy G, Brunt EM, Caldwell SH.Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;6: 1384-91.
72. Reeves HL, Friedman SL. Activation of hepatic stellate cells— a key issue in liver fibrosis. Front Biosci. 2002;7:808-26
73. Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol. 2013;4): 1473-92.
74. Geerts, A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin. Liver Dis. 2001 ;21 :31 1-335
75. Brun PJ, Yang KJ, Lee SA, Yuen JJ, Blaner WS. Retinoids: Potent regulators of metabolism. Biofactors. 2013 2): 151-63.
Claims
1. A method of treating or preventing a pancreatic disease in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARp).
2. The method of Claim 1, wherein said pancreatic disease is associated with obesity.
3. The method of Claim 1, wherein said pancreatic disease is caused by a high fat diet.
4. The method of Claim 1, wherein said pancreatic disease is diabetes.
5. The method of Claim 1, wherein said diabetes is type I or type II diabetes, or gestational diabetes.
6. The method of Claim 1, wherein said pancreatic disease is associated with reduced vitamin A level in the pancreas.
7. A method of treating or preventing the degeneration of pancreatic beta cells in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
8. A method of maintaining or improving the function of pancreatic beta cells in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
9. A method of maintaining or improving pancreatic insulin secretion in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
10. A method of maintaining or improving insulin sensitivity in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARp).
1 1. A method of maintaining or improving the level of glucagon in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARp).
12. A method of treating or preventing fat deposit in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
13. A method of treating or preventing inflammation in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
14. A method of decreasing oxidative stress in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
15. The method of Claim 12, 13 or 14, wherein said fat deposit, inflammation or oxidative stress is in an organ of said subject.
16. The method of Claim 15, wherein said organ is pancreas, liver, kidney or testes.
17. A method of increasing RARP level in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
18. The method of Claim 17, wherein said RAR level is increased in an organ.
19. The method of Claim 18, wherein said organ is pancreas, liver, kidney or testes.
20. A method of decreasing the level of an inflammatory mediator in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARp).
21. The method of Claim 20, wherein said production of said inflammatory mediator is decreased.
22. The method of Claim 20, wherein said secretion of said inflammatory mediator is decreased.
23. The method of Claim 20, wherein said inflammatory mediator is monocyte chemotactic protein (mcp-1) or tumor necrosis factor alpha (inf-a).
24. The method of anyone of Claims 20-23, wherein said level of inflammatory mediator is decreased in an organ.
25. The method of Claim 24, wherein said organ is pancreas, liver, kidney or testes.
26. A method of treating or preventing a liver disease in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
27. The method of Claim 26, wherein said liver disease is associated with obesity.
28. The method of Claim 26, wherein said liver disease is associated with a high fat diet.
29. The method of Claim 26, wherein said liver disease is fatty liver disease (FLD), liver fibrosis, or hepatic steatosis.
30. The method of Claim 26, wherein said liver disease is associated with reduced vitamin A level in the liver.
31. The method of Claim 26, wherein said liver disease is non-alcoholic FLD (NAFLD), alcohol associated FLD, or non-alcoholic steatohepatitis (NASH).
32. A method of decreasing the activation of hepatic stellate cells (HSCs) in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
33. A method of decreasing the level of hepatic reactive oxygen species (ROS) in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
34. A method of decreasing the level of alpha smooth muscle actin (a-SMA) in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RAR ).
35. The method of Claim 34, wherein said subject has a disease of non-alcoholic FLD (NAFLD), alcohol associated FLD, or non-alcoholic steatohepatitis (NASH).
36. A method of increasing the level of lethicin:retinol acyltransferase (LRAT) in the liver of a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
37. A method of increasing the level of RARP in the liver of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARp).
38. A method of decreasing the level of SRBPlc in the liver of a subject comprising administering to the subject vitamin A or an agonist of retinoic acid receptor-beta (RARp).
39. A method of treating or preventing a kidney disease in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARp).
40. The method of Claim 39, wherein said kidney disease is associated with obesity.
41. The method of Claim 39, wherein said kidney disease is associated with a high fat diet.
42. The method of Claim 39, wherein said kidney disease is kidney fibrosis.
43. The method of Claim 39, wherein said kidney disease is a chronic kidney disease.
44. The method of Claim 39, wherein said kidney disease is associated with a pancreatic disease.
45. The method of Claim 39, wherein said kidney disease is associated with a liver disease.
46. The method of Claim 39, wherein said kidney disease is associated with reduced vitamin A level in the kidney.
47. A method of increasing the level of lethicin:retinol acyltransferase (LRAT) in the kidney of a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
48. A method of treating or preventing a disease associated with an organ-specific vitamin A deficiency in a subject comprising administering to said subject vitamin A or an agonist of retinoic acid receptor-beta (RARP).
49. The method of Claim 48, wherein said organ-specific vitamin A deficiency is associated with obesity.
50. The method of Claim 48, wherein said organ-specific vitamin A deficiency is associated with a high fat diet.
51. The method of Claim 48, wherein said subject has a normal serum level of vitamin A.
52. The method of Claim 48, wherein said subject has a normal serum level of retinyl esters.
53. The method of Claim 48, wherein said organ is pancreas, liver, kidney or testes.
54. A method of treating or preventing fibrosis in a subject comprising administering to said subject an agonist of retinoic acid receptor-beta (RARP).
55. A method of decreasing the accumulation of fat in a subject comprising administering to said subject an agonist of retinoic acid receptor-beta (RARP).
56. The method of Claim 54, wherein said fibrosis is in pancreas, liver, kidney or testes.
57. The method of Claim 55, wherein said accumulation of fat is in pancreas, liver, kidney or testes.
58. The method according to any one of claims 1 to 58, wherein said vitamin A or agonist of retinoic acid receptor-beta (RAR ) is administered three times daily.
59. The method according to any one of claims 1 to 58, wherein said vitamin A or agonist of retinoic acid receptor-beta (RAR ) is administered at an amount from about 30 mg to about 200 mg per day.
60. The method of Claim 59, wherein said agonist is administered at an amount from about 50 mg to about 150 mg per day.
61. The method of Claim 59, wherein said agonist is administered at an amount from about 50 mg to about 100 mg per day.
62. The method of Claim 59, wherein said agonist is administered at an amount from about 100 mg to about 150 mg per day.
63. The method according to any one of claims 1 to 58, wherein said vitamin A or agonist of retinoic acid receptor-beta (RAR ) is administered orally.
64. The method according to any one of claims 1 to 58, wherein said vitamin A or agonist of retinoic acid receptor-beta (RAR ) is administered intravenously or subcutaneously.
65. The method according to any one of claims 1 to 58, wherein said agonist of retinoic acid receptor-beta (RAR ) does not elevate serum triglyceride in said subject.
66. The method according to any one of claims 1 to 58, wherein said agonist of retinoic acid receptor-beta (RAR ) does not increase cardiovascular risk in said subject.
67. The method according to any one of claims 1 to 58, wherein a therapeutic effective amount of said vitamin A or agonist of RAR is administered.
68. The method according to any one of claims 1 to 58, comprising both vitamin A and an agonist of RARp.
69. The method according to any one of claims 1 to 58, wherein said agonist is a highly specific RAR agonist.
70. The method according to any one of claims 1 to 58, wherein said agonist is AC261066.
71. The method according to any one of claims 1 to 58, wherein said agonist is AC55649.
72. A pharmaceutical composition comprising vitamin A or an agonist of retinoic acid receptor-beta (RARP) or a pharmaceutically acceptable salt thereof at an amount from about 10 mg to about 60 mg.
73. The pharmaceutical composition of Claim 72, wherein said amount of the vitamin A or agonist is from 15 mg to about 50 mg.
74. The pharmaceutical composition of Claim 72, wherein said amount of the vitamin A or agonist is from 15 mg to about 35 mg.
75. The pharmaceutical composition of Claim 72, wherein said amount of the vitamin A or agonist is from about 35 mg to about 50 mg.
76. The pharmaceutical composition of Claim 72, wherein said amount of the vitamin A or agonist is from about 30 mg to about 200 mg.
77. The pharmaceutical composition of Claim 72, wherein said amount of the vitamin A or agonist is from about 50 mg to about 150 mg.
78. The pharmaceutical composition of Claim 72, wherein said amount of the vitamin A or agonist is from about 50 mg to about 100 mg.
79. The pharmaceutical composition of Claim 72, wherein said amount of the vitamin A or agonist is from about 100 mg to about 150 mg.
80. A pharmaceutical composition comprising vitamin A or an agonist of retinoic acid receptor-beta (RARP) or a pharmaceutically acceptable salt thereof at a concentration from about 0.1 mg to about 10 mg per 100 ml.
81. The pharmaceutical composition of Claim 72, wherein said concentration is from about 0.5 mg to about 5 mg per 100 ml.
82. The pharmaceutical composition of Claim 72, wherein said concentration is from about 1 mg to about 2.5 mg per 100 ml.
83. The pharmaceutical composition of Claim 72, comprising both vitamin A and an agonist of RARp.
84. The pharmaceutical composition according to any one of claims 72 to 83, wherein said agonist is a highly specific RAR agonist.
85. The pharmaceutical composition according to any one of claims 72 to 83, wherein said agonist is AC261066.
86. The pharmaceutical composition according to any one of claims 72 to 83, wherein said agonist is AC55649.
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2935334A CA2935334C (en) | 2013-01-18 | 2014-01-17 | Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists |
EP14740346.3A EP2945701B1 (en) | 2013-01-18 | 2014-01-17 | Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists |
US14/761,341 US9585857B2 (en) | 2013-01-18 | 2014-01-17 | Methods of treating diseases associated with high-fat diet and vitamin A deficiency using retinoic acid receptor agonists |
PCT/US2015/011820 WO2015109231A1 (en) | 2014-01-17 | 2015-01-16 | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
CA2937107A CA2937107C (en) | 2014-01-17 | 2015-01-16 | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
US15/112,159 US11160769B2 (en) | 2014-01-17 | 2015-01-16 | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
EP15737537.9A EP3094380B1 (en) | 2014-01-17 | 2015-01-16 | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
CN201580012615.9A CN106211757B (en) | 2014-01-17 | 2015-01-16 | Methods of treating metabolic syndrome-related conditions using retinoic acid receptor agonists |
US15/414,128 US10010512B2 (en) | 2013-01-18 | 2017-01-24 | Methods of treating diseases associated with high-fat diet and vitamin A deficiency using retinoic acid receptor agonists |
US16/000,003 US10525019B2 (en) | 2013-01-18 | 2018-06-05 | Methods of treating diseases associated with high-fat diet and vitamin a deficiency using retinoic acid receptor agonists |
US16/008,946 US11191755B2 (en) | 2014-01-17 | 2018-06-14 | Compositions and methods for providing cardioprotective effects |
US16/677,780 US11207277B2 (en) | 2013-01-18 | 2019-11-08 | Methods of treating diseases associated with high-fat diet and vitamin a deficiency using retinoic acid receptor agonists |
US17/515,796 US20220304945A1 (en) | 2014-01-17 | 2021-11-01 | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
US17/542,852 US20220296579A1 (en) | 2014-01-17 | 2021-12-06 | Compositions and methods for providing cardioprotective effects |
US17/855,772 US20220347163A1 (en) | 2014-01-17 | 2022-06-30 | Compositions and methods for providing cardioprotective effects |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361754438P | 2013-01-18 | 2013-01-18 | |
US61/754,438 | 2013-01-18 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/761,341 A-371-Of-International US9585857B2 (en) | 2013-01-18 | 2014-01-17 | Methods of treating diseases associated with high-fat diet and vitamin A deficiency using retinoic acid receptor agonists |
PCT/US2015/011820 Continuation-In-Part WO2015109231A1 (en) | 2014-01-17 | 2015-01-16 | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
US15/112,159 Continuation-In-Part US11160769B2 (en) | 2014-01-17 | 2015-01-16 | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
US15/414,128 Continuation US10010512B2 (en) | 2013-01-18 | 2017-01-24 | Methods of treating diseases associated with high-fat diet and vitamin A deficiency using retinoic acid receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014113695A1 true WO2014113695A1 (en) | 2014-07-24 |
Family
ID=51210101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/012083 WO2014113695A1 (en) | 2013-01-18 | 2014-01-17 | Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists |
Country Status (4)
Country | Link |
---|---|
US (4) | US9585857B2 (en) |
EP (1) | EP2945701B1 (en) |
CA (2) | CA3114497A1 (en) |
WO (1) | WO2014113695A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015109231A1 (en) * | 2014-01-17 | 2015-07-23 | Cornell University | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
US11191755B2 (en) | 2014-01-17 | 2021-12-07 | Cornell University | Compositions and methods for providing cardioprotective effects |
US11331851B2 (en) | 2016-11-08 | 2022-05-17 | Koninklijke Philips N.V. | Filled cavity three-dimensional printed objects and methods for production |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3806839A4 (en) * | 2018-06-14 | 2022-03-30 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | Compositions and methods for providing cardioprotective effects |
WO2023044355A1 (en) * | 2021-09-15 | 2023-03-23 | Cornell University | Compositions and methods for mitigating alcohol liver disease |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0698392A1 (en) | 1994-08-02 | 1996-02-28 | L'oreal | Compositions containing a RAR alpha specific ligand and at least one fatty acid |
WO1997010819A1 (en) | 1995-09-18 | 1997-03-27 | Ligand Pharmaceuticals Incorporated | Treating niddm with rxr agonists |
WO1999029330A1 (en) | 1997-12-05 | 1999-06-17 | Viva America Marketing, Inc. | Composition and method for treating nonalcoholic steatohepatitis |
WO2002080935A1 (en) | 2001-04-04 | 2002-10-17 | Ortho Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
US20060189798A1 (en) * | 1987-12-16 | 2006-08-24 | Institut Pasteur | Novel steroid/thyroid hormone receptor-related gene, which is inappropriately expressed in human heptocellular carcinoma, and which is a retinoic acid receptor |
WO2007009083A2 (en) | 2005-07-12 | 2007-01-18 | Acadia Pharmaceuticals Inc. | Compounds with activity at retinoic acid receptors |
US20090137671A1 (en) | 2007-05-17 | 2009-05-28 | Noy Noa | Methods of treating metabolic disorders |
WO2010088375A2 (en) * | 2009-01-28 | 2010-08-05 | Virginia Tech Intellectual Properties, Inc. | Method of synergistically enhancing the therapeutic efficacy and safety of medications through a combination therapy |
CA2802414A1 (en) * | 2010-06-17 | 2011-12-22 | Nitto Denko Corporation | Agent for treating renal fibrosis |
WO2012125724A1 (en) | 2011-03-14 | 2012-09-20 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of proliferative disorders |
WO2012162698A1 (en) | 2011-05-26 | 2012-11-29 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of immune disorders |
WO2012175698A1 (en) * | 2011-06-23 | 2012-12-27 | Université Libre de Bruxelles | Therapeutic use of all-trans retinoic acid (atra) in patients suffering from alcoholic liver disease |
WO2012178108A1 (en) | 2011-06-24 | 2012-12-27 | Glycoregimmune, Inc. | Prevention and treatment of inflammatory conditions |
-
2014
- 2014-01-17 CA CA3114497A patent/CA3114497A1/en active Pending
- 2014-01-17 US US14/761,341 patent/US9585857B2/en active Active
- 2014-01-17 EP EP14740346.3A patent/EP2945701B1/en active Active
- 2014-01-17 CA CA2935334A patent/CA2935334C/en active Active
- 2014-01-17 WO PCT/US2014/012083 patent/WO2014113695A1/en active Application Filing
-
2017
- 2017-01-24 US US15/414,128 patent/US10010512B2/en active Active
-
2018
- 2018-06-05 US US16/000,003 patent/US10525019B2/en active Active
-
2019
- 2019-11-08 US US16/677,780 patent/US11207277B2/en active Active
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060189798A1 (en) * | 1987-12-16 | 2006-08-24 | Institut Pasteur | Novel steroid/thyroid hormone receptor-related gene, which is inappropriately expressed in human heptocellular carcinoma, and which is a retinoic acid receptor |
EP0698392A1 (en) | 1994-08-02 | 1996-02-28 | L'oreal | Compositions containing a RAR alpha specific ligand and at least one fatty acid |
AU2723295A (en) | 1994-08-02 | 1996-02-29 | C.I.R.D. Galderma | Method and compositions for stimulating the differentiation of preadipocytic cells and associated therapeutic treatments |
WO1997010819A1 (en) | 1995-09-18 | 1997-03-27 | Ligand Pharmaceuticals Incorporated | Treating niddm with rxr agonists |
WO1999029330A1 (en) | 1997-12-05 | 1999-06-17 | Viva America Marketing, Inc. | Composition and method for treating nonalcoholic steatohepatitis |
WO2002080935A1 (en) | 2001-04-04 | 2002-10-17 | Ortho Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
WO2007009083A2 (en) | 2005-07-12 | 2007-01-18 | Acadia Pharmaceuticals Inc. | Compounds with activity at retinoic acid receptors |
US20090137671A1 (en) | 2007-05-17 | 2009-05-28 | Noy Noa | Methods of treating metabolic disorders |
US20120316242A1 (en) * | 2007-05-17 | 2012-12-13 | Case Western Reserve University | Methods of treating metabolic disorders |
WO2010088375A2 (en) * | 2009-01-28 | 2010-08-05 | Virginia Tech Intellectual Properties, Inc. | Method of synergistically enhancing the therapeutic efficacy and safety of medications through a combination therapy |
CA2802414A1 (en) * | 2010-06-17 | 2011-12-22 | Nitto Denko Corporation | Agent for treating renal fibrosis |
WO2012125724A1 (en) | 2011-03-14 | 2012-09-20 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of proliferative disorders |
WO2012162698A1 (en) | 2011-05-26 | 2012-11-29 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of immune disorders |
WO2012175698A1 (en) * | 2011-06-23 | 2012-12-27 | Université Libre de Bruxelles | Therapeutic use of all-trans retinoic acid (atra) in patients suffering from alcoholic liver disease |
WO2012178108A1 (en) | 2011-06-24 | 2012-12-27 | Glycoregimmune, Inc. | Prevention and treatment of inflammatory conditions |
Non-Patent Citations (19)
Title |
---|
AHMAD ET AL.: "Naturally Occurring Antioxidant Vitamin Levels in Patients with Type-II Diabetes Mellitus", J AYUB MED COLL ABBOTTABAD, vol. 15, no. 1, 1 January 2003 (2003-01-01), pages 54 - 7, XP008179934 * |
ALBRECHTSSON ET AL., PANCREAS, vol. 25, no. 1, 2002, pages 49 - 56 |
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19 |
CHARBONNEL BPENFORNIS AVARROUD-VIAL MKUSNIK-JOINVILLE ODETOURNAY B: "Insulin therapy for diabetes mellitus: Treatment regimens and associated costs", DIABETES & METABOLISM, 13 December 2011 (2011-12-13) |
CHERTOW ET AL.: "Effects of Vitamin A Deficiency and Repletion on Rat Glucagon Secretion", PANCREAS, vol. 9, no. 4, 1 July 1994 (1994-07-01), pages 475 - 484, XP008179935 * |
CHERTOW ET AL.: "Effects of Vitamin A Deficiency and Repletion on Rat Insulin Secretion In Vivo and In Vitro from Isolated Islets", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 79, 1 January 1987 (1987-01-01), pages 163 - 169, XP055266509 * |
EUN-JUNG RHEE ET AL., DIABETES & METABOLISM JOURNAL, vol. 36, no. 3, 2012, pages 167 - 180 |
FORD ET AL.: "The Metabolic Syndrome and Antioxidant Concentrations: Findings from the Third National Health and Nutrition Examination Survey", DIABETES, vol. 52, 1 September 2003 (2003-09-01), pages 2346 - 2352, XP055266350 * |
GUARIGUATA LWHITING DWEIL CUNWIN N: "The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults", DIABETES RESEARCH AND CLINICAL PRACTICE, vol. 94, no. 3, December 2011 (2011-12-01), pages 322 - 32, XP028336869, DOI: 10.1016/j.diabres.2011.10.040 |
HUANG ESBASU AO'GRADY MCAPRETTA JC: "Projecting the future diabetes population size and related costs for the U.S. Diabetes Care", RESEARCH SUPPORT, N.I.H., EXTRAMURAL RESEARCH SUPPORT, NON-U.S. GOV'T, vol. 32, no. 12, December 2009 (2009-12-01), pages 2225 - 9 |
OLIVER-KRASINSKI JMSTOFFERS DA: "On the origin of the beta cell", GENES & DEVELOPMENT. [RESEARCH SUPPORT, N.I.H., EXTRAMURAL REVIEW, vol. 22, no. 15, 1 August 2008 (2008-08-01), pages 1998 - 2021 |
PIERRE-JACQUES BRUN ET AL., BIOFACTORS, vol. 39, no. 2, 2012, pages 151 - 163 |
See also references of EP2945701A4 |
SORIA BANDREU EBERNA GFUENTES EGIL ALEON-QUINTO TMARTIN FMONTANYA ENADAL AREIG JA: "Engineering pancreatic islets", PFLIIGERS ARCHIV - EUROPEAN JOURNAL OF PHYSIOLOGY, vol. 440, no. l, 2000, pages 1 - 18 |
WALDRON-LYNCH FHEROLD KC: "Immunomodulatory therapy to preserve pancreatic beta-cell function in type 1 diabetes", NATURE REVIEWS DRUG DISCOVERY. [REVIEW, vol. 10, no. 6, June 2011 (2011-06-01), pages 439 - 52 |
WALDRON-LYNCH FVON HERRATH MHEROLD KC: "Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass", NOVARTIS FOUNDATION SYMPOSIUM, vol. 292, 2008, pages 146 - 55 |
WHITING DRGUARIGUATA LWEIL CSHAW J: "IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030", DIABETES RESEARCH AND CLINICAL PRACTICE. [RESEARCH SUPPORT, NON-U.S. GOV'T, vol. 94, no. 3, December 2011 (2011-12-01), pages 311 - 21, XP028336868, DOI: 10.1016/j.diabres.2011.10.029 |
ZARET KSGROMPE M: "Generation and regeneration of cells of the liver and pancreas", SCIENCE. [RESEARCH SUPPORT, N.I.H., EXTRAMURAL RESEARCH SUPPORT, NON-U.S. GOV'T REVIEW, vol. 322, no. 5907, 5 December 2008 (2008-12-05), pages 1490 - 4, XP009171074, DOI: 10.1126/science.1161431 |
ZOBALI ET AL.: "Effects of vitamin A and insulin on the antioxidative state of diabetic rat heart: a comparison study with combination treatment", CELL BIOCHEMISTRY AND FUNCTION, vol. 20, 1 June 2002 (2002-06-01), pages 75 - 80, XP055213644 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015109231A1 (en) * | 2014-01-17 | 2015-07-23 | Cornell University | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
EP3094380A4 (en) * | 2014-01-17 | 2017-10-25 | Cornell University | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
US11160769B2 (en) | 2014-01-17 | 2021-11-02 | Cornell University | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
US11191755B2 (en) | 2014-01-17 | 2021-12-07 | Cornell University | Compositions and methods for providing cardioprotective effects |
US11331851B2 (en) | 2016-11-08 | 2022-05-17 | Koninklijke Philips N.V. | Filled cavity three-dimensional printed objects and methods for production |
Also Published As
Publication number | Publication date |
---|---|
US10525019B2 (en) | 2020-01-07 |
US20150352070A1 (en) | 2015-12-10 |
CA2935334A1 (en) | 2014-07-24 |
CA3114497A1 (en) | 2014-07-24 |
US9585857B2 (en) | 2017-03-07 |
EP2945701B1 (en) | 2023-04-05 |
US20190029973A1 (en) | 2019-01-31 |
US10010512B2 (en) | 2018-07-03 |
US20170135964A1 (en) | 2017-05-18 |
US11207277B2 (en) | 2021-12-28 |
EP2945701A1 (en) | 2015-11-25 |
EP2945701A4 (en) | 2016-09-14 |
CA2935334C (en) | 2021-05-25 |
US20200078318A1 (en) | 2020-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11207277B2 (en) | Methods of treating diseases associated with high-fat diet and vitamin a deficiency using retinoic acid receptor agonists | |
US20220304945A1 (en) | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists | |
Linnemann et al. | Pancreatic β-cell proliferation in obesity | |
Purwana et al. | GABA promotes human β-cell proliferation and modulates glucose homeostasis | |
Gupta et al. | The role of peroxisome proliferator‐activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus | |
Wang et al. | Puerarin ameliorates hyperglycemia in HFD diabetic mice by promoting β-cell neogenesis via GLP-1R signaling activation | |
Bähr et al. | GLUT4 in the endocrine pancreas–indicating an impact in pancreatic islet cell physiology? | |
Kuang et al. | Dapper1 attenuates hepatic gluconeogenesis and lipogenesis by activating PI3K/Akt signaling | |
Kim et al. | A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression | |
Pan et al. | Glucose, metformin, and AICAR regulate the expression of G protein-coupled receptor members in INS-1 β cell | |
Lei et al. | Histone deacetylase 3-selective inhibitor RGFP966 ameliorates impaired glucose tolerance through β-cell protection | |
US20220323408A1 (en) | Composition used for combating metabolic diseases and uses of composition | |
US11491117B2 (en) | Compounds for the prevention and treatment of glucose intolerance related conditions and obesity | |
KR101491108B1 (en) | Direct preparation of functional insulin producing cell from human dermal fibroblasts | |
Zhang et al. | Niacin exacerbates β cell lipotoxicity in diet-induced obesity mice through upregulation of GPR109A and PPARγ2: Inhibition by incretin drugs | |
WO2021117824A1 (en) | Incretin production accelerator and sugar uptake accelerator | |
Napolitano | Gfi1: a new target for diabetes therapy | |
Moon et al. | Pancreatic beta‐cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes | |
Cardia et al. | Isolated ileal interposition in enteroendocrine L cells differentiation | |
de Azevedo | Isolated ileal interposition in enteroendocrine L cells differentiation. | |
Oliveira | Effect of Antidiabetic Drugs in Human Sertoli Cells: Implications for Male Fertility | |
Zocchi et al. | Abscisic acid: a promising molecule in the treatment of type 2 diabetes mellitus and its complications | |
Gu | NeuroD is required for maintaining functionally mature β cells in pancreatic islets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14740346 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014740346 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14761341 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2935334 Country of ref document: CA |